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Summary (298282/300 words) 27 
Background: The interleukin-23/Th17 pathway is implicated in psoriatic arthritis pathogenesis. 28 
Guselkumab, a an interleukin-23-inhibitor that specifically binds the IL23p19-subunit, human 29 
anti-interleukin-23p19-subunit monoclonal antibody, significantly and safely improved psoriatic 30 
arthritis in a Phase-2 study. 31 
Methods: This Phase-3, double-blind, placebo-controlled study (118 sites in 13 countries) 32 
enrolled biologic-naïve patients with active psoriatic arthritis (≥5 swollen, ≥5 tender joints, 33 
C-reactive-protein ≥0·6mg/dL) despite standard therapies. Patients were randomised (1:1:1; 34 
computer-generated permuted blocks; stratified by baseline disease-modifying antirheumatic 35 
drug use and C-reactive-protein) to subcutaneous guselkumab 100mg every-4-weeks (q4w); 36 
guselkumab 100mg at Weeks 0, 4, every-8-weeks (q8w); or placebo. The primary endpoint was 37 
ACR20 response at Week24 among randomized and treated patients. Clinicaltrials.gov 38 
identifier-NCT03158285 (active-not recruiting). 39 
Findings: From 07/13/2017–03/06/2019, 739 randomised patients received guselkumab q4w 40 
(N=245), q8w (N=248), or placebo (N=246); 716 patients continued treatment through Week24. 41 
Significantly greater proportions of guselkumab q4w- (156 [63·74%] of 245; 95% confidence 42 
interval: 57%, 70%) and q8w- (159 [64·1%] of 248; 95% confidence interval: 58%, 70%) than 43 
placebo- (81 [32·93%] of 246; 95% confidence interval: 27%, 39%) treated patients achieved 44 
Week24 ACR20 response (% differences [95% confidence intervals]: 30·81 (22·4, 39·1) and 45 
31·2 (22·93, 39·540), respectively; both p<0·0001). Both guselkumab regimens significantly 46 
improved psoriasis, enthesitis, dactylitis, physical function, and quality-of-life vs. placebo at 47 
Week24. Mean changes in total modified van der Heijde-Sharp scores at Week24 were 48 
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significantly (0·29) and numerically (0·52) lower with guselkumab q4w and q8w, respectively, 49 
than placebo (0·95; p=0.011 and p=0.07). Through Week24, serious adverse events, and 50 
specifically serious infections, occurred in eight (3·3%) and three (1·2%) of 245 patients 51 
receiving guselkumab q4w, three (1·2%) and one (0·4<1%) of 248 receiving guselkumab q8w, 52 
and seven (2·83%) and one (0·4<1%) of 246 receiving placebo, respectively. No deaths 53 
occurred. 54 
Interpretation: Guselkumab, a human anti-interleukin-23p19-subunit monoclonal antibody that 55 
specifically inhibits interleukin-23 by binding the cytokine’s p19-subunit, was efficacious and 56 
well tolerated in patients with active psoriatic arthritis who were biologic naive. These data 57 
support the further development of guselkumab for treating psoriatic arthritis.  58 
Funding: Janssen Research & Development, LLC  59 
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Panel - Research in context 60 
Evidence before this study – Current literature indicates that interleukin-23 is instrumental in 61 
driving the chronic inflammation associated with several immune-mediated diseases, including 62 
psoriasis and psoriatic arthritis. Guselkumab is a high-affinity, anti-interleukin-23p19-subunit 63 
specific human monoclonal antibody that specifically bind’s the cytokine’s p19-subunit and is 64 
approved to treat moderate-to-severe psoriasis. In a Phase-2 study, selective blockade of 65 
interleukin-23 by guselkumab significantly improved signs and symptoms of active psoriatic 66 
arthritis and was well tolerated during 1 year of exposure.  67 
Added value of this study – Results of this pivotal study, the larger of two comprising the first 68 
Phase-3 program investigating a novel mechanism of action to treat psoriatic arthritis, confirm 69 
that targeting the p19-subunit of interleukin-23 effectively treats the diverse domain 70 
manifestations of psoriatic arthritis. Specifically, in patients with active disease despite non-71 
biologic disease-modifying antirheumatic, apremilast, and/or nonsteroidal anti-inflammatory 72 
drug treatment, but no prior exposure to biologics, subcutaneous guselkumab 100 mg 73 
significantly improved joint symptoms, dactylitis, enthesitis, psoriasis, physical function, and 74 
quality of life when administered every 4 or 8 weeks. Progression of structural damage through 75 
Week24 was significantly lower with guselkumab q4w, and numerically lower with q8w, dosing 76 
vs. placebo, providing initial evidence of inhibition of radiographic progression by an 77 
interleukin-23 inhibitor that target its p19-subunit inhibitor. The guselkumab safety profile in 78 
psoriatic arthritis patients was comparable to profiles observed in placebo-treated psoriatic 79 
arthritis patients and guselkumab-treated patients with psoriasis.  80 
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Implications of all the available evidence – Consistent with previous findings of a proof-of-81 
concept study confirming that interleukin-23 plays a critical role in the pathogenesis of psoriatic 82 
arthritis, these Phase-3 trial data provide pivotal evidence that guselkumab offers a novel 83 
mechanism of action to treat the diverse clinical manifestations of psoriatic arthritis and inhibit 84 
structural damage progression.  85 
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INTRODUCTION 86 
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with peripheral joint 87 
inflammation, enthesitis, dactylitis, axial disease, and cutaneous and nail involvement, all of 88 
which can significantly limit physical function and impair quality of life. While the introduction 89 
of biologic (e.g., tumor necrosis factor-α inhibitors [TNFi], ustekinumab, interleukin [IL]-17A 90 
inhibitors, abatacept) and oral (e.g., apremilast, tofacitinib) agents has increased the extent and 91 
duration of achievable clinical responses, there remains a need for new therapies are needed that 92 
canto treat the diverse manifestations of PsA while maintaining a favorable risk-benefit profile.1 93 
The origins of the varying clinical manifestations of PsA remain under study. The IL-23/T-helper 94 
cell 17 (Th17) pathway – via downstream IL-17 expression - appears critical to skin 95 
manifestations. IL-23 can also induce IL-22, a cytokine implicated in enthesitis and bone 96 
formation,2 and, in part via IL-17A and TNF induction, elicit the joint symptoms and damage 97 
that are hallmarks of PsA. IL-23 is a heterodimer formed by pairing of the p19-subunit with a 98 
and p40-subunits, the latter of which is shared with IL-12. Although IL-12 and IL-23 share the 99 
p40-subunit, they also encompass unique p35- (for IL-12) and p19- (for IL-23) subunits.3,4 100 
Whereas IL-23 has been determined to be a predominant promoter of autoimmune-mediated 101 
articular inflammation, IL-12 more likely facilitates protection from autoimmune inflammation 102 
and T-cell exhaustion.4-7  The divergent roles of these closely related cytokines are highlighted by 103 
differential skin effects, whereby abnormal differentiation of keratinocytes is triggered by IL-23, 104 
but not IL-12,6 and differing roles in the body’s response to bacterial and viral infections, as well 105 
as tumour control via their regulation of T-cell function.5 Targeting the p19-subunit of IL-23, and 106 
thus sparing IL-12, has demonstrated robust efficacy in psoriasis,37-6 10 suggesting a prominent 107 
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upstream position in the inflammatory hierarchy across the psoriatic disease spectrum, which 108 
thereby merits evaluation of selective IL-23p19-subunit inhibition via IL23-p19 binding in PsA.  109 
Guselkumab (Janssen Biotech, Inc., Horsham, PA, USA), a high-affinity, human monoclonal 110 
antibody that binds specifically to the p19-subunit of IL-23, is approved to treat patients with 111 
moderate-to-severe psoriasis who are candidates for systemic and/or phototherapy. In a 112 
randomised, placebo-controlled, Phase-2 study evaluating the efficacy and safety of 113 
subcutaneous guselkumab 100 mg at Weeks 0, 4 and every 8 weeks (q8w) in 149 patients with 114 
active PsA, including ≥3% body surface area (BSA) of psoriasis, guselkumab demonstrated 115 
efficacy across all endpoints related to joint signs and symptoms, physical function, skin disease, 116 
enthesitis, dactylitis, and health-related quality of life.711   117 
Herein, we report 24-week results from one of two Phase-3 trials, i.e., DISCOVER-2, conducted 118 
to evaluate guselkumab in the treatment of biologic-naïve patients with active PsA. DISCOVER-119 
2 evaluations included joint and skin manifestations, as well as structural damage. Results from 120 
the other registrational trial of guselkumab in PsA (DISCOVER-1), which aimed to enroll 121 
patients with a broader range of baseline levels of disease activity, some of whom were 122 
previously treated with one or two TNFi, are reported elsewhere (Lancet.org doi.xxxx).  123 
124 
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METHODS 125 
Study design 126 
This Phase-3, randomised, double-blind, placebo-controlled, multicenter, 3-arm study of 127 
guselkumab in patients with active PsA, who were biologic-naïve and demonstrated inadequate 128 
response to standard therapies (non-biologic disease-modifying antirheumatic drugs [DMARDs], 129 
apremilast, and/or nonsteroidal anti-inflammatory drugs [NSAIDs]), was conducted at 118 sites 130 
in 13 countries worldwide (see Online Supplement)Bulgaria, Czech Republic, Estonia, Latvia, 131 
Lithuania, Malaysia, Poland, Russia, Spain, Taiwan, Turkey, Ukraine, USA). Screening began 132 
on 07/13/2017, and; the final Week-24 visit occurred on 02/25/2019. The trial design includes a 133 
6-week screening period; a 100-week treatment phase, with a placebo-controlled period from 134 
Week0–Week24 and an active treatment period from Week24–Week100; and 12-weeks of safety 135 
follow-up after the last administration of study agent. At Week16, all patients with <5% 136 
improvement in both swollen and tender joint counts were eligible for early escape, in which the 137 
investigator could initiate or increase the dose of NSAIDs or other analgesics (up to the regional 138 
marketed dose approved), oral corticosteroids (≤10 mg/day of prednisone or equivalent dose), or 139 
non-biologic DMARDs (limited to methotrexate ≤25 mg/week, sulfasalazine ≤3g/day, 140 
hydroxychloroquine ≤400 mg/day, or leflunomide ≤20 mg/day). Study results through Week24 141 
are reported. This trial (NCT03158285) is being conducted per Declaration of Helsinki and Good 142 
Clinical Practice guidelines. The protocol (available at Lancet.org) was approved by each site’s 143 
governing ethical body.  144 
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Participants 145 
Approximately 684 eligible patients were planned for this study. Adults with PsA for ≥6 months, 146 
fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR)8 12 and with ≥5 tender and 147 
≥5 swollen joints; C-reactive protein (CRP) ≥0·6 mg/dL; current or documented history of 148 
psoriasis; and either inadequate response to, or intolerance of, standard non-biologic treatment 149 
were eligible. Standard treatment included ≥3 months of non-biologic DMARDs, ≥4 months of 150 
apremilast at the approved dose (if discontinued >4 weeks before receiving study agent), or 151 
≥4 weeks of NSAIDs for PsA. Previous exposure to biologic agents or Janus kinase inhibitors 152 
precluded study entryparticipation. Patients were permitted, but not required, to continue stable 153 
baseline use of stable doses of selected non-biologic DMARDs (limited to those allowed for 154 
early escape as detailed above), and NSAIDs/other analgesics. Only one DMARD was permitted 155 
through Week52. Patients also had to meet screening criteria for screening laboratory test 156 
resultsevaluations and tuberculosis (TB) history/ and testing results (including /treatment (for 157 
latent TB if present). Full inclusion and exclusion criteria, and further details of permitted and 158 
prohibited therapies, are included in the protocol (Lancet.org doi.xxxx). All patients provided 159 
written informed consent.  160 
Randomisation and masking 161 
At Week0, patients were centrally randomised using an interactive web response system (with 162 
computer-generated permuted-block randomisation stratified by baseline non-biologic DMARD 163 
use [yes/no] and the most recent high-sensitivity serum CRP value prior to randomization 164 
[<2·0/≥2·0 mg/dL]) in a 1:1:1 ratio to receive guselkumab 100 mg every 4 weeks (q4w); 165 
guselkumab 100 mg at Week0, Week4, and every 8 weeks (q8w); or placebo. Patients, 166 
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investigators, and study site staff were blinded to treatment assignment. Placebo and guselkumab 167 
were provided in identical prefilled syringes with non-identifying labels. Patients in each 168 
treatment group received the same number of injections at the same time pointsBlinding was 169 
accomplished as reported for DISCOVER-1 (Lancet.org doi.xxxx). 170 
Procedures  171 
Guselkumab was administered as a 100-mg subcutaneous injection at Week0, Week4, and then 172 
q4w or q8w. Dose selection for DISCOVER-2 was as described for DISCOVER-1 (Lancet.org 173 
doi.xxxx). Clinical efficacy and safety assessments were performed at screening, baseline, 174 
Week2, Week4, and q4w through Week24. An independent joint assessor evaluated 66 joints for 175 
swelling, 68 joints for tenderness, and determined the presence/severity of enthesitis (Leeds 176 
Enthesitis Index [LEI]) and dactylitis. Dactylitis severity for each finger and toedigit was scored 177 
on a scale of 0–3 (as 0–no dactylitis, 1–mild dactylitis, 2–moderate dactylitis, or 3–severe 178 
dactylitis;  (total score 0–60). Serum pharmacokinetic and immunogenicity assessments are as 179 
reported for DISCOVER-1 (Lancet.org doi.xxxx). As well, details of joint (American College of 180 
Rheumatology [ACR] response, 28-joint Disease Activity Score incorporating CRP [DAS28-181 
CRP]), skin (Investigator’s Global Assessment of psoriasis [IGA], Psoriasis Area and Severity 182 
Index [PASI]), physical function (Health Assessment Questionnaire-Disability Index [HAQ-183 
DI]), health-related quality of life (36-item Short-Form [SF-36] Health Survey), and safety 184 
(adverse events [AEs], routine haematology and chemistry assessment, electronic Columbia-185 
Suicide Severity Rating Scale [eC-SSRS] questionnaires) assessments are as reported for 186 
DISCOVER-1 (Lancet.org doi.xxxx). 187 
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In DISCOVER-2, single radiographs of the hands (posteroanterior) and feet (anteroposterior) 188 
were obtained at screening and Week24. The rRadiographs were evaluated independently by two 189 
central readers (, who were blinded to the order of the radiographs and clinical data), with the 190 
van der Heijde-Sharp (vdH-S) score modified for PsA (, i.e., with the addition of distal 191 
interphalangeal joints of the hands added).9 13 Adjudication was employed as mandated by 192 
primary reader disagreement. The total PsA-modified vdH-S score (0–528) sums the joint 193 
erosion score (0–320; 0–no erosions, 5–extensive loss of bone from >50% of the articulating 194 
bone) and the joint space narrowing (JSN) score (0–208; 0–no JSN, 4–complete loss of joint 195 
space, bony ankylosis, or complete luxation). The average score of the two readers was used 196 
employed in the analyses. 197 
Outcomes 198 
The primary endpoint was the proportion of patients achieving ACR20 response rate at Week24. 199 
Major secondary endpoints included ACR50 and ACR70 responses, changes from baseline in the 200 
DAS28-CRP scores, IGA skin response (score=0/1 and ≥2-grade improvement from baseline) 201 
among patients with ≥3% BSA of psoriasis and IGA≥2 (mild-to-severe psoriasis) at baseline, 202 
changes from baseline in HAQ-DI and PsA-modified vdH-S scores, changes from baseline in, 203 
and resolution of, enthesitis and dactylitis pooled across both DISCOVER-1&2 trials (see 204 
Statistical analyses), changes in the SF-36 physical/mental component summary (PCS/MCS) and 205 
mental component summary (MCS) scores, all at Week24, and ACR20 and /ACR50 responses at 206 
Week16. Other selected key secondary outcomes included clinically meaningful improvement 207 
(≥0.35) in HAQ-DI scores in patients with baseline HAQ-DI scores ≥0·35, ≥75/90/100% 208 
improvement in the PASI (PASI75/PASI90/PASI100) in patients with mild-to-severe psoriasis at 209 
baseline, and minimal disease activity (MDA; see Lancet.org doi.xxxx), all at Week24. Safety 210 
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outcomes were as reported for DISCOVER-1 (Lancet.org doi.xxxx).  included AEs, serious AEs 211 
(SAEs), AEs resulting in discontinuation of study drug, infections, injection-site reactions, 212 
malignancies, major adverse cardiovascular events (MACE; i.e., cardiovascular death, nonfatal 213 
myocardial infarction, or nonfatal stroke), suicidal ideation or behavior (based on eC-SSRS 214 
questionnaire or reported AEs), and clinical laboratory abnormalities classified by National 215 
Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE) grades.  216 
Statistical analyses 217 
Assuming Week24 ACR20 response rates of 45% with guselkumab versus 25% with placebo, 218 
684 patients (228/treatment group) were required to provide ~99% statistical power (α=0·05; 219 
2-sided). With 684 patients, the study was estimated to have 90% power to detect a treatment 220 
difference in change from baseline in total PsA-modified vdH-S scores, assuming mean changes 221 
from baseline at Week24 of 0·9 and 0·3, respectively, in placebo- and across all guselkumab-222 
treated patientswith placebo and guselkumab  and a standard deviation of 2·5 for each treatment. 223 
Strategies employed to control the overall Type 1 error rate are described below. 224 
Efficacy analyses through Week24 included all randomised patients who received ≥1 225 
administration of study treatment and were conducted according to assigned treatment groups 226 
(full analysis set). Treatment differences for binary endpoints were assessed via a Cochran-227 
Mantel-Haenszel test; those for continuous endpoints employed an analysis of covariance model.  228 
To increase sample size, endpoints related to enthesitis and dactylitis among the smaller number 229 
of patients with those conditions at baseline were prespecified to be tested by pooling data from 230 
this study with those from DISCOVER-1 (Lancet.org doi.xxxx). Results of these pooled analyses 231 
are presented herein. 232 
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Owing to differences in health authority requirements for multiplicity control between the United 233 
States (US) and other countries, two graphical testing procedures were prespecified to control 234 
overall Type I error at α=0·05 (2-sided). For both approaches, the primary endpoint (ACR20 235 
response at Week24) was first tested for the q4w group and then for the q8w group (each at 0·05 236 
level). The first graphical procedure (Figure S1A) controlled the overall Type 1 error rate across 237 
both dosing regimens at the 0·05 level for the primary and the following major secondary 238 
endpoints at Week24: IGA skin response among patients with mild-to-severe psoriasis; changes 239 
in HAQ-DI, PsA-modified vdH-S, and SF-36 PCS scores; resolution of dactylitis and enthesitis 240 
among patients with the respective condition at baseline pooled across both DISCOVER trials, 241 
and changes in SF-36 MCS scores. Results of this testing procedure are presented in the main 242 
manuscript text and those from the second graphical procedure (Figure S1B), which controlled 243 
the overall Type 1 error rate for each dosing regimen at the 0·05 level for all major secondary 244 
endpoints, except changes from baseline in enthesitis and dactylitis scores at Week24, with two 245 
parallel procedures, are provided online (Table S1). For endpoints not controlled for multiplicity, 246 
unadjusted (nominal) p values provided should be interpreted only as supportive. 247 
Data handling rules were applied to all clinical efficacy analyses. Patients who met treatment-248 
failure criteria (discontinued study agent, terminated study participation, initiated or increased 249 
DMARD or oral corticosteroid doses, initiated protocol-prohibited PsA treatment) were 250 
considered nonresponders for binary endpoints and as having no improvement from baseline for 251 
continuous endpoints. Missing data were imputed as nonresponders for binary endpoints and 252 
using multiple imputation for continuous endpoints. For radiographic endpoints, treatment failure 253 
rules were not applied, and missing data (five in guselkumab q4w group, one in guselkumab q8w 254 
group, one in placebo group) were imputed using multiple imputation.  255 
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An independent data monitoring committee examined data on an ongoing basis through the 256 
Week24 database lock to ensure the safety of the study participants. Statistical analyses were 257 
performed using SAS version 9.4 with SAS/STAT version 14.2 (SAS Institute, Inc., Cary, NC, 258 
USA). This active (not recruiting) study was registered in Clinicaltrials.gov (NCT03158285). 259 
Role of the funding source 260 
Janssen Research and Development, LLC funded this trial. All authors, including employees of 261 
Janssen (APK, ECH, XLX, SS, PA, BZ, YZ), were involved in data collection, analysis, and/or 262 
interpretation; trial design; manuscript preparation; and the decision to submit the paper for 263 
publication. Janssen provided funding to a professional medical writer who assisted with 264 
manuscript preparation and submission. The corresponding author (PJM) had full access to all 265 
study data and final responsibility to submit for publication.  266 
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RESULTS 267 
From 1,153 screened patients, 741 were randomised. Patients failed screening most often for 268 
serum CRP levels <0·6 mg/dL. Overall, 739 randomised patients were treated with guselkumab 269 
q4w (N=245), guselkumab q8w (N=248), or placebo (N=246) and included in the full analysis 270 
set. At Week16, 12 (4·95%) of 245 guselkumab q4w-, 13 (5·2%) of 248 guselkumab q8w-, and 271 
38 (15·4%) of 246 placebo-treated patients had <5% improvement in both tender and swollen 272 
joint counts and qualified for early escape, of which seven (2·93%) of 245 guselkumab q4w-, six 273 
(2·4%) of 248 guselkumab q8w-, and 14 (5·76%) of 246 placebo-treated patients initiated or 274 
increased the dose of NSAIDs, oral corticosteroids, and/or permitted non-biologic DMARDs. 275 
Overall,  23 (3·1%) of 739 treated patients discontinued study agent, most commonly due to 276 
AEs, resulting in robust patient retention through Week24 (Figure 1).  277 
Baseline characteristics were generally well balanced across randomised groups. Modest 278 
numerical differences were observed between the guselkumab and placebo groups for the 279 
proportions of males, severity of psoriasis assessed by the PASI score, and presence of dactylitis 280 
and enthesitis at study outset. Background medication use was consistent across randomised 281 
treatment groups; among the 739 treated patients, 512 (69·3%) were receiving non-biologic 282 
DMARDs, including 443 (59·960%) receiving MTX, 145 (19·620%) were receiving oral 283 
corticosteroids for PsA, and 504 (68·2%) reported NSAID use at baseline (Table 1). 284 
Major protocol deviations were evenly distributed between guselkumab- (35 [7%] of 493) and 285 
placebo- (23 [9%] of 246) treated patients. Overall, 11 patients (five guselkumab, six placebo) 286 
entered the study without satisfying all criteria, six (four guselkumab, two placebo) received the 287 
incorrect treatment/dose), six received a disallowed medication (three guselkumab, three 288 
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placebo), and one (guselkumab) met a withdrawal criterion but was not withdrawn. No deviation 289 
was considered to impact overall results. 290 
For the study’s primary endpoint, significantly greater proportions of patients in the guselkumab 291 
q4w (156 [63·74%] of 245; 95% confidence interval [CI]: 57%, 70%) and q8w (159 [64·1%] of 292 
248; 95% CI: 58%, 70%) groups than in the placebo group (81 [32·93%] of 246; 95% CI: 27%, 293 
39%) groups achieved an ACR20 response at Week24 (% differences [95% confidence interval 294 
(CIs): 30·81 [22·4, 39·1] and 31·2 [22·93, 39·540], respectively; both p<0·0001; Table 2). 295 
Results of all prespecified sensitivity analyses were consistent with the primary analysis (data on 296 
file).  297 
A consistent treatment benefit was observed for the primary efficacy endpoint for both 298 
guselkumab dosing regimens across patient subgroups defined by demography, baseline disease 299 
characteristics, and prior and baseline medication use. In particular, ACR20 response at Week24 300 
was consistent in the subgroup of patients with MTX use at baseline (q4w: 92 [63%] of 146 and 301 
q8w: 85 [60%] of 141), 302 
With both guselkumab dosing regimens, more patients achieved ACR20 response vs. placebo by 303 
Week4 (following one injection of guselkumab); response rates continued to increase through 304 
Week24 (Figure 2A).  ACR50 and ACR70 response rates were also consistently higher with both 305 
guselkumab dosing regimens vs. placebo (Figures 2B, 2C). Higher rates of ACR20 response at 306 
Week16, ACR50 response at Week16 and Week24, and ACR70 response at Week24 were 307 
observed among guselkumab q4w- and q8w-treated than placebo-treated patients. Further, 308 
greater improvements in DAS28-CRP scores at Week24 were observed with guselkumab q4w 309 
(LS mean change: -1·62)) and q8w (-1·59) vs. placebo (-0·97; Table 2). 310 
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Among DISCOVER-1 (Lancet.org doi.xxxx) and DISCOVER-2 patients with the respective 311 
manifestations at baseline, dactylitis resolved at Week24 in significantly higher proportions of 312 
guselkumab q4w- (101 [63·54%] of 159) and q8w- (95 [59·4%] of 160) than placebo- (65 313 
[42·2%] of 154) treated patients (p=0·0110 and p=0·0301, respectively). Resolution of enthesitis 314 
was also observed in significantly higher proportions of guselkumab q4w- (109 [44·95%] of 315 
243) and q8w- (114 [49·650%] of 230) than placebo- (75 [29·4%] of 255) treated patients (both 316 
p=0·0301) when combined across both trials. Improvements from baseline in the enthesitis LEI 317 
and dactylitis scores at Week24 were also numerically greater with both guselkumab dosing 318 
regimens than placebo when pooled across DISCOVER-1 and DISCOVER-2 (Table 3), and 319 
consistent trends were observed in the individual trials (Table 3S2). 320 
Patients treated with guselkumab q4w demonstrated significantly less progression of structural 321 
damage, as reflected by smaller changes from baseline in the PsA-modified vdH-S score at 322 
Week24, than placebo-treated patients (LS mean [95% CI]: 0·29 [-0·05, 0·63] vs. 0·95 [0·61, 323 
1·29], respectively; p=0·0110). Guselkumab administered q8w resulted in numerically less 324 
radiographic progression (LS mean [95% CI]: 0·52 [0·18, 0·86]) than placebo, but the treatment 325 
difference did not achieve statistical significance (p=0·07; Table 2). A probability plot of 326 
changes in modified vdH-S scores from baseline at Week24 is provided in Figure S2. 327 
In patients with mild-to-severe psoriasis at baseline, guselkumab q4w and q8w significantly 328 
improved skin disease, as assessed by IGA response rates, at Week24 vs. placebo (126 [68·5%] 329 
of 184 and 124 [70·5%] of 176, respectively vs. 35 [19·1%] of 183; both p<0·0001; Table 2, 330 
Figure 2D). PASI75, PASI90, and PASI100 response rates were also higher among guselkumab- 331 
than placebo-treated patients (Table 2).  332 
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Guselkumab q4w and q8w significantly improved HAQ-DI scores from baseline at Week24 vs. 333 
placebo (LSmean [95% CI] changes: -0·40 [-0·46, -0·34] and -0·37 [-0·43, -0·31], respectively, 334 
vs. -0·13 [-0·19, -0·07]; both p<0·0001). The proportions of patients with improvement in the 335 
HAQ-DI score ≥0·35 at Week24, among those with baseline HAQ-DI ≥0·35, also indicated that 336 
guselkumab q4w (128 [56·1%] of 228) and q8w (114 [50·0%] of 228) improved physical 337 
function to a greater extent than placebo (74 [31·4%] of 236; Table 2). 338 
Patients started the study with impaired health-related quality-of-life as assessed by mean SF-36 339 
PCS (32·4–33·3) and MCS (47·2–48·4) scores (US general population norm=50.0). Significant 340 
improvements in SF-36 PCS scores from baseline at Week24 were demonstrated by guselkumab  341 
q4w and q8w, respectively, vs. placebo (LSmean changes: 7·04 and 7·39 vs. 3·42; both 342 
p=0·0110). Numerical improvements in SF-36 MCS scores (4·22 and 4·17 vs. 2·14; both 343 
p=0·07) were also observed for both guselkumab dosing regimens vs. placebo; although the 344 
lower bounds of the 95% CIs of the differences from placebo exceeded 0, differences were not 345 
significant after multiplicity adjustment (Table 2). At Week24, MDA was achieved by 46 346 
(18·89%) of 245 and 62 (25·0%) of 248 patients receiving guselkumab  q4w and q8w, 347 
respectively, vs. 15 (6·1%) of 246 placebo-treated patients (Table 2).  348 
An overview of guselkumab pharmacokinetic and immunogenicity findings can be found in the 349 
Online Supplement.Four hundred ninety-two patients who had serum samples collected 350 
following subcutaneous administration of guselkumab were evaluable for pharmacokinetic 351 
analysis. The median steady-state trough serum guselkumab concentration was 3·35 µg/mL at 352 
Week12, which was maintained through Week24 (3·98 µg/mL) with guselkumab 100 mg q4w 353 
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dosing. The median steady-state trough serum guselkumab concentration was 1·05 µg/mL when 354 
guselkumab 100 mg was given at Week0, Week4, and then q8w.  355 
Antibodies to guselkumab were detected in 10 (2·0%) of 490 guselkumab-treated patients with 356 
evaluable samples through Week24. None of these patients tested positive for neutralizing 357 
antibodies to guselkumab. Additional findings related to anti-drug antibodies are reported in the 358 
Online Supplement. 359 
Guselkumab was generally well-tolerated. Through Week24, AEs were reported by 113 (46·1%) 360 
of 245, 114 (46·0%) of 248, and 100 (40·71%) of 246 patients receiving guselkumab q4w, 361 
guselkumab q8w, and placebo, respectively. Serious AEs (SAEs) were reported by eight (3·3%) 362 
of 245, three (1·2%) of 248, and seven (2·83%) of 246 patients, and AEs led to discontinuation 363 
of study agent for six (2·4%) of 245, two (0·81%) of 248, and four (1·62%) of 246 patients 364 
receiving guselkumab q4w, guselkumab q8w, and placebo, respectively (Table 4).  365 
The AEs reported by ≥3% of patients in any treatment group were infections (upper respiratory 366 
tract infection, nasopharyngitis, bronchitis) and laboratory investigations (alanine 367 
aminotransferase [ALT] increased, aspartate aminotransferase [AST] increased; Table 4). 368 
Serious infections occurred in three (1·2%) of 245 patients receiving guselkumab q4w (acute 369 
hepatitis B [de novo], influenza pneumonia, oophoritis), one (<10·4%) of 248 patients receiving 370 
guselkumab q8w (pyrexia [likely of urinary origin]), and one (0·4<1%) of 246 placebo-treated 371 
patients (post-procedural fistula). No Candida or opportunistic infections, or cases of active TB, 372 
occurred through Week24. No AEs of inflammatory bowel disease were reported in guselkumab-373 
treated patients, whereas there was one suspected case in the placebo group through Week24.  374 
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No deaths were reported through Week24. One patient in each of the guselkumab q4w (at Week2 375 
only) and placebo (pre-existing and at Week12) groups experienced suicidal ideation (Level 1 – 376 
wish to be dead); no patient reported suicidal or self-injurious behavior without suicidal intent 377 
through Week24. Two patients were diagnosed with a malignancy through Week24 (guselkumab 378 
q8w: melanoma in situ at Week4; placebo: clear-cell renal cell carcinoma at Week12). One 379 
patient had a major acute cardiovascular event: a 58-year-old female with a history of 380 
hypertension, hyperlipidemia, and diabetes and who was receiving guselkumab 100 mg q4w had 381 
an ischaemic stroke at Week20. The patient recovered, and study drug was discontinued.  382 
Two patients demonstrated maximum National Cancer Institute Common Terminology Criteria 383 
for AEs (CTCAENCI-CTCAE) Grade-3 or 4 neutropenia, one in the placebo group (Grade-3 384 
[<1·0–0·5 x 109/L] at Week 8 only) and one in the guselkumab q4w group (did not recur upon 385 
retest the following week, not associated with infections or study drug interruptions). No other 386 
NCI-CTCAE Grade-3 or higher hematology abnormalities were observed in guselkumab-treated 387 
patients, except a case of anemia in one guselkumab q8w-treated patient (Grade-3 hemoglobin 388 
[<80·0 g/L] of 69 g/L at Week16 only). 389 
The proportions of patients with increased ALT or AST levels reported as AEs appeared slightly 390 
higher in the guselkumab than placebo groups (Table 4). The overall incidences of maximum 391 
NCI-CTCAE Grade-2 (>3.0–5.0 x upper limit of normal [ULN]) ALT and AST increases were 392 
low and slightly more common in guselkumab- (nine [1·82%] and 11 [2·2%] of 490 patients, 393 
respectively) than placebo- (four [1·62%] and none of 246 patients, respectively) treated patients. 394 
Maximum NCI-CTCAE Grade-3 (>5·0–20·0 x ULN) or Grade-4 (>20·0 x ULN) ALT values 395 
were observed in four (1·62%) of 243 patients receiving guselkumab q4w (all Grade-3), three 396 
(1·2%) of 247 patients receiving guselkumab q8w (all Grade-3), and two (0·81%) of 246 397 
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placebo-treated patients (one patient each with Grade-3 and Grade-4 values). For AST, 398 
maximum NCI-CTCAE Grade-3 (>5·0–20·0 x ULN) or Grade-4 (>20·0 x ULN) values were 399 
observed in five (2·1%) of 243 patients receiving guselkumab q4w (all Grade-3), one (0·4<1%) 400 
of 247 patients receiving guselkumab q8w (Grade-3), and two (0·81%) of 246 placebo-treated 401 
patients (all Grade-3). These laboratory abnormalities resulted in study drug discontinuation in 402 
one placebo-treated patient (Week8 ALT/AST of 1053/665 U/L related to serious isoniazid-403 
induced hepatitis that resolved by Week12) and two patients receiving guselkumab q4w (one 404 
with Week4 ALT/AST of 479/484 U/L related to non-serious AE of isoniazid-induced hepatitis 405 
that resolved by Week16 and one with Week20 ALT/AST of 373/238 U/L related to an SAE of 406 
acute hepatitis B with no clinically significant increase in bilirubin; AEs were resolving at the 407 
last contact).   408 
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DISCUSSION  409 
Results of the Phase-3, multicenter, randomised, double-blind, placebo-controlled, DISCOVER-410 
2 study through Week24 indicate that guselkumab, a selective IL-23 inhibitor that binds the 411 
cytokine’s p19-subunit, effected robust improvements in signs and symptoms of joint disease in 412 
patients with PsA. The study met its primary endpoint for both guselkumab 100 mg q4w and 413 
q8w, with 63·74% and 64·1% of these patients, respectively, achieving an ACR20 response at 414 
Week24, compared with 32·93% of placebo-treated patients. Similarly, ACR50 and ACR70 415 
response rates demonstrated that treatment with guselkumab results in clinically meaningful 416 
reductions in the joint signs and symptoms of PsA. Improvement occurred at early timepoints 417 
and increased over time through Week24. 418 
Guselkumab, whether administered q4w or q8w, also elicited significant improvements in skin 419 
psoriasis, physical function, and health-related quality of life, all of which significantly impact 420 
mental health, work productivity, and the economic burden of PsA.134,145 Of particular note, 421 
>60% of guselkumab-treated patients achieved PASI90 and 45% achieved PASI100 responses at 422 
Week24. These findings are consistent with the established efficacy of guselkumab in treating 423 
moderate-to-severe plaque psoriasis.37,59,610  Guselkumab q4w inhibited progression of structural 424 
damage vs. placebo at Week24, based on changes in the PsA-modified vdH-S score. 425 
Guselkumab q8w dosing also reduced structural damage progression, but the difference from 426 
placebo was not statistically significant. This observation could derive from differences in total 427 
guselkumab exposure between q4w and q8w dosing from Weeks0-24. Radiographic data being 428 
collected through 1 year will provide additional data with which to evaluate the ability of the 429 
q8w dosing regimen to limit progression of structural damage. 430 
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Inflammation of periarticular tissues, i.e., such as dactylitis and enthesitis, is a hallmark of PsA 431 
that can present a treatment challenge.10 16 IL-23 is essential for both activating Th17 cells, which 432 
produce IL-17A, and maintaining IL-17A production thereafter.  IL-17A has been implicated 433 
mechanistically in both inflammation and bone remodeling in a murine model of rheumatoid 434 
arthritis by stimulating osteoclastogenesis; promoting bone resorption in fetal mouse long bones; 435 
and inducing expression of the receptor activator of nuclear factor kappa-B-ligand (RANKL), an 436 
osteoclast differentiation factor, in osteoclast-supporting cells.11 In addition, IL-23 can induce 437 
IL-22, a cytokine implicated in enthesitis and bone formation.2 IL-23 also regulates innate cells 438 
(e.g., γδ T, natural killer T, and innate lymphoid cell subsets), which are predominantly located 439 
in non-lymphoid tissue and, upon stimulation by IL-23, produce pro-inflammatory cytokines (IL-440 
17, IL-22, and interferon-γ), thereby inducing local tissue inflammation.17-20 Given that 441 
guselkumab 100 mg q8w has been shown to decrease serum IL-17A concentrations of PsA 442 
patients to levels observed in healthy controls by Week16,12 21 it is not unexpected that both 443 
guselkumab dosing regimens afforded significantly higher proportions of patients with clinically 444 
resolved dactylitis and enthesitis at Week24 when data were pooled across the DISCOVER-1 445 
and DISCOVER-2 trials.  446 
As a downstream effector cytokine of IL-23, IL-17A has been implicated mechanistically in both 447 
inflammation and bone remodeling in a murine rheumatoid arthritis model by stimulating 448 
osteoclastogenesis; promoting bone resorption in fetal mouse long bones; and inducing 449 
expression of the receptor activator of nuclear factor kappa-B-ligand, an osteoclast 450 
differentiation factor, in osteoclast-supporting cells.22 IL-23 can also induce IL-22, a cytokine 451 
implicated in bone formation.2 Because IL-23 regulates several effector cytokines that are 452 
thought to contribute to PsA disease pathology, inhibition of multiple effector cytokines through 453 
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IL-23 targeting may provide more effective modulation of these processes than single cytokine 454 
inhibition.  Selective IL-23p19-subunit inhibition with guselkumab q4w also inhibited 455 
progression of structural damage relative to placebo at Week24, as evidenced by changes from 456 
baseline in the PsA-modified vdH-S score. Guselkumab q8w dosing also reduced structural 457 
damage progression relative to placebo, but this difference did not achieve statistical 458 
significance. Radiographic data being collected through 1 year differences between the two 459 
guselkumab dosing regimens in their ability to limit progression of structural damage.  460 
Guselkumab, whether administered q4w or q8w, also elicited significant improvements in skin 461 
psoriasis, physical function, and health-related quality of life, all of which significantly impact 462 
mental health, work productivity, and the economic burden of PsA.13,14 Of particular note, >60% 463 
of guselkumab-treated patients achieved PASI90 and 45% achieved PASI100 responses at 464 
Week24. These findings are consistent with the established efficacy of guselkumab in treating 465 
moderate-to-severe plaque psoriasis.3,5,6  466 
Both regimens of gGuselkumab 100 mg waswere generally well tolerated in this PsA population, 467 
without any no clinically meaningful differences in safety between q4w and q8w dosing through 468 
Week24. No Candida or opportunistic infections or cases of active TB occurred. One suspected 469 
case of inflammatory bowel disease was reported in a placebo-treated patient. There was no 470 
apparent association between the development of antibodies to guselkumab and the occurrence 471 
of injection-site reactions (see Online Supplement). The overall safety profile was generally 472 
consistent with that reported for patients with psoriasis.37,59,15 23 Specifically, guselkumab 473 
100 mg q8w demonstrated a stable safety profile through 100 weeks of treatment, with no safety 474 
signals with regard to serious infection, malignancy, MACE, or suicidality, in an analysis of data 475 
from more than 1,800 patients enrolled in two Phase-3 psoriasis studies.15 23 Further, in more 476 
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than >800 patients with psoriasis who participated in the VOYAGE-1 study, no new safety 477 
signals were observed through up to 4 years of guselkumab 100 mg when given q8w.1624   478 
IL-12 and IL-23 are proinflammatory cytokines known to facilitate autoimmunity and associated 479 
inflammation.17 Although IL-12 and IL-23 share a common p40-subunit, they also encompass 480 
unique p35- (in the case of IL-12) and p19- (in the case of IL-23) subunits.18,19 Whereas IL-23 481 
has been determined to be a predominant promoter of autoimmune-mediated articular 482 
inflammation, IL-12 more likely facilitates protection from autoimmune inflammation and T-cell 483 
exhaustion.17,19  The divergent roles of these closely related cytokines are highlighted by 484 
differential skin effects, whereby abnormal differentiation of keratinocytes is triggered by IL-23, 485 
but not IL-12,20 and differing roles in the body’s response to bacterial and viral infections, as 486 
well as tumour control via their regulation of T-cell function.17 In DISCOVER-2, inhibition of 487 
IL-23 by selectively targeting its p19-subunit was well tolerated and demonstrated robust 488 
efficacy across clinical domains that have been identified as crucial to achieving PsA remission 489 
(e.g., synovitis, enthesitis, dactylitis, psoriasis).21 As such, it appears that inhibiting the p19-490 
subunit of IL-23, but not the p40-subunit it shares with IL-12, is a novel mechanism by which to 491 
safely and effectively treat the diverse manifestations of PsA.  492 
The biologic-naïve patients enrolled into DISCOVER-2 patients presented with an average of 493 
12–13 swollen and 20–22 tender joints, along with substantial systemic inflammation (median 494 
serum CRP: 1·2–1·3 mg/dL), possibly limiting the applicability of findings to patients with less 495 
active disease. The relatively high placebo response rates observed for joint (ACR20-33%) and 496 
skin (IGA-19%) outcomes may also affect data interpretation. However, these response rates are 497 
consistent with other recently reported findings in biologic-naïve PsA populations,25,26 and likely 498 
reflect higher expectations for efficacy as more potent therapies have become available for PsA. 499 
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It will be important to evaluate whether the favourable responses and safety profile through 500 
Week24 are maintained; such data are being collected throughout this 2-year study. 501 
Thus, guselkumab was well tolerated and demonstrated robust efficacy in DISCOVER-2 across 502 
clinical domains crucial to achieving PsA remission (e.g., synovitis, enthesitis, dactylitis, 503 
psoriasis), including reducing structural damage progression.27 By binding to IL-23’s p19-504 
subunit, but not the p40-subunit it shares with IL-12, guselkumab targets the key upstream 505 
regulatory cytokine responsible for the Th17 pathway implicated in PsA, thereby providing a 506 
targeted yet comprehensive means of controlling the downstream inflammatory cascade and thus 507 
safely and effectively treating PsA’s diverse manifestations. 508 
In conclusion, these Phase-3 trial data provide pivotal evidence that the high-affinity, human, 509 
anti-IL-23p19-subunit monoclonal antibody guselkumab offers a novel mechanism of action to 510 
treat the diverse manifestations of active PsA, including reducing structural damage progression.  511 
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FIGURE LEGENDS 649 
Figure 1. Patient disposition through Week 24. Two patients (1-guselkumab q4w, 1-placebo 650 
were randomized in error and never treated). CRP – C-reactive protein, q4/8w – every 4/8 weeks, 651 
TB – tuberculosis, W/D – withdrawal 652 
Figure 2. Proportions of patients achieving ACR20 (A), ACR50 (B), ACR70 (C), and 653 
Psoriasis IGA (D) responses over time (FAS). ACR20/50/70 – American College of 654 
Rheumatology 20/50/70% improvement, FAS – full analyses set, IGA – Investigator’s Global 655 
Assessment, q4/8w – every 4/8 weeks  656 
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TABLES 657 
Table 1. Summary of baseline patient characteristics (FAS)  
 Guselkumab 100 mg  
Placebo 
q4w q8w 
Number of patients  245 248 246 
Age (years) 45·9 (11·5) 44·9 (11·9) 46·3 (11·7) 
Male, n (%) 142 (58·0%) 129 (52·0%) 117 (47·68%) 
White, n (%) 242 (98·89%) 240 (96·87%) 242 (98·4%) 
Body weight (kg) 85·8 (19·5) 83·0 (19·31) 84·0 (19·7) 
PsA duration (years) 5·53 (5·9) 5·11 (5·5) 5·75 (5·6) 
Number of swollen joints (0-66) 12·9 (7·8) 11·7 (6·8) 12·3 (6·9) 
Number of tender joints (0-68) 22·4 (13·5) 19·8 (11·9) 21·6 (13·06) 
Patient's assessment of pain (0-10 cm VAS) 6·2 (2·0) 6·3 (2·0) 6·3 (1·8) 
Patient's global assessment (arthritis, 0-10 cm VAS) 6·4 (1·9) 6·5 (1·9) 6·5 (1·8) 
Physician's global assessment (0-10 cm VAS) 6·6 (1·5) 6·6 (1·6) 6·6 (1·5) 
HAQ-DI score (0-3) 1·2 (0·6) 1.3 (0.6) 1·3 (0·6) 
CRP (mg/dL), median (IQR) 1·2 (0·6–2·3) 1·3 (0·7–2·5) 1·2 (0·5–2·6) 
Psoriatic BSA, % 18·2 (20·4%)  17·0 (21·0%) 17·1 (20·0%) 
IGA score=3/4, n (%) 117 (47·8%) 108 (43·54%) 115 (46·97%) 
PASI score (0-72) 10·8 (11·7) 9·7 (11·7) 9·3 (9·8) 
PsA-modified vdH-S score (0-528) 27·2 (42·2) 23·0 (37·8) 23·8 (37·8) 
Patients with enthesitis, n (%) 170 (69·4%) 158 (63·74%) 178 (72·4%) 
  Enthesitis (LEI) score (1-6)a 3·0 (1·7) 2·6 (1·5) 2·8 (1·6) 
Patients with dactylitis, n (%) 121 (49·4%) 111 (44·85%) 99 (40·2%) 
  Dactylitis score (1-60)b 8·6 (9·6) 8·0 (9·6) 8·4 (9·3) 
SF-36    
  PCS score 33·3 (7·1) 32·6 (7·9) 32·4 (7·0) 
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Table 1. Summary of baseline patient characteristics (FAS)  
 Guselkumab 100 mg  
Placebo 
q4w q8w 
  MCS score 48·4 (11·0) 47·4 (10·8) 47·2 (12·0) 
Patients with prior apremilast use, n (%) 5 (2%) 4 (2%) 4 (2%) 
Patients receiving at baseline, n (%)    
 DMARDs 170 (69·4%) 170 (68·5%) 172 (69·970%) 
   Methotrexate 146 (59·60%) 141 (56·960%) 156 (63·4%) 
  Dose (mg/week)  15·6 (5·0) 15·3 (5·2) 15·2 (4·6) 
 Oral corticosteroids for PsA 46 (18·89%) 50 (20·2%) 49 (19·920%) 
  Dose equivalent to prednisone (mg/day) 7·0 (2·4) 6·8 (2·5) 7·8 (2·5) 
 NSAIDs for PsA 171 (69·870%) 165 (66·5%) 168 (68·3%) 
Data presented are mean (SD) unless noted otherwise.  
a Among patients with LEI enthesitis score at baseline  (q4w, n=166; q8w, n=157; placebo, n=175)  
b Among patients with dactylitis score at baseline  (q4w, n=121; q8w, n=111; placebo, n=99)  
BSA – body surface area, CRP – C-reactive protein, DMARDs – disease-modifying antirheumatic drugs, FAS – full 
analysis set (randomised and treated patients), HAQ-DI – Health Assessment Questionnaire- Disability Index, IGA 
– Investigator’s Global Assessment, IQR -  interquartile range, LEI – Leeds Enthesitis Index, MCS – mental 
component summary, NSAIDs – nonsteroidal anti-inflammatory drugs, PASI – Psoriasis Area and Severity Index, 
PCS – physical component summary, PsA – psoriatic arthritis, q4w/q8w – every 4/8 weeks, SD – standard 
deviation, SF-36 – 36-item Short-Form, TNF – tumor necrosis factor, VAS – visual analog scale, vdH-S - van der 
Heijde-Sharp 
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Table 2. Summary of efficacy findings through Week24 (FASa) 
 Guselkumab 100 mg  
Placebo 
 q4w q8w 
Number of patients  245 248 246 
Primary endpoint    
ACR20 response at Week24, n (%) 156 (63·74%)   159 (64·1%)   81 (32·93%) 
  % difference vs placebo (95% CI) 30·81 (22·4, 39·1)  31·2 (22·93, 39·540)  
  US procedureb-adjusted p value <0·0001 <0·0001  
Major secondary endpoints controlled by US procedure   
Psoriasis IGA response at Week24c, n/N (%) 126/184 (68·5%)  124/176 (70·5%)  35/183 (19·1%) 
  % difference vs placebo (95% CI) 49·850 (41·2, 58·4) 50·951 (42·2, 59·760)  
  US procedureb-adjusted p value <0·0001 <0·0001  
HAQ-DI, LSmean (95% CI) change at Week24  -0·40 (-0·46, -0·34) -0·37 (-0·43, -0·31) -0·13 (-0·19, -0·07) 
  LSmean difference vs placebo (95% CI) -0·27 (-0·35, -0·19) -0·24 (-0·32, -0·15)  
  US procedureb-adjusted p value <0·0001 <0·0001  
PsA-modified vdH-S,  Median (IQR) change at 
Week24LSmean (95% CI) change at Week24  
0.29 (-0.05, 0.63) 
0·00 (-0·50–0·50) 
0·52 (0·18, 0·86) 0.00 
(-0.50–1.00) 
0·95 (0·61, 
1·29)0·00 (0·00–
1·00) 
 LSmean (95% CI) change at Week24 0·29 (-0·05, 0·63) 0·52 (0·18, 0·86) 0·95 (0·61, 1·29) 
  LSmean difference vs placebo (95% CI) -0.66 (-1.13, -0.19) -0·43 (-0·90, 0·03)  
  US procedureb-adjusted p value 0·0110 0·07  
SF-36 PCS, LSmean (95% CI) change at Week24  7·04 (6·14, 7·94) 7·39 (6·50, 8·29) 3·42 (2·53, 4·32) 
  LSmean difference vs placebo (95% CI)  3·62 (2·39, 4·85) 3·97 (2·7475, 5·20)  
  US procedureb-adjusted p value 0·0110 0·0110  
SF-36 MCS, LSmean (95% CI) change at Week24 4·22 (3·14, 5·29) 4·17 (3·10, 5·23) 2·14 (1·07, 3·2122) 
  LSmean difference vs placebo (95% CI) 2·07 (0·60, 3·54)  2·02 (0·56, 3·49)  
  US procedureb-adjusted p value 0·07 0·07  
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Major secondary endpoints not controlled by US procedure   
ACR20 response at Week16, n (%) 137 (55·96%) 137 (55·2%)  83 (33·74%)  
  % difference vs placebo (95% CI) 22·2 (13·74, 30·71) 21·52 (13·1, 30·0)   
  Unadjusted p valued <0·0001 <0·0001  
ACR50 response at Week24, n (%) 81 (33·1%) 78 (31·52%)  35 (14·2%)  
  % difference vs placebo (95% CI) 18·89 (11·52, 26·1) 17·2 (10·0, 24·4)   
  Unadjusted p valued <0·0001 <0·0001  
ACR50 response at Week16, n (%) 51 (20·81%)  71 (28·69%)  23 (9·3%) 
  % difference vs placebo (95% CI) 11·52 (5·2, 17·78) 19·3 (12·63, 25·96)  
  Unadjusted p valued <0·0010004 <0·0001  
ACR70 response at Week24, n (%) 32 (13·1%) 46 (18·5%)  10 (4·1%)  
  % difference vs placebo (95% CI)   9·0 (4·1, 13·84) 14·5 (9·1, 19·920)  
  Unadjusted p valued <0·0010004 <0·0001  
DAS28-CRP, LSmean (95% CI) change at Week24  -1·62 (-1·76, -1·49) -1·59 (-1·72, -1·45) -0·97 (-1·11, -0·84) 
  LSmean difference vs placebo (95% CI) -0·65 (-0·83, -0·47) -0·61 (-0·80, -0·43)  
  Unadjusted p valued <0·0001 <0·0001  
Additional secondary endpoints not controlled by US procedure   
HAQ-DI improvement ≥0.35e at Week24, n/N (%) 128/228 (56·1%)  114/228 (50·0%)  74/236 (31·4%) 
  % difference vs placebo (95% CI) 24·4 (15·86, 33·0) 18·79 (10·0, 27·3)  
  Unadjusted p valued <0·0001 <0·0001  
PASI75 response at Week24c, n/N (%)  144/184 (78·3%)  139/176 (79·0%)  42/183 (23·0%) 
  % difference vs placebo (95% CI) 55·4 (47·0, 63·84) 55·76 (47·2, 64·2)  
  Unadjusted p valued <0·0001 <0·0001  
PASI90 response at Week24 c, n/N (%) 112/184 (60·91%) 121/176 (68·89%) 18/183 (9·810%) 
  % difference vs placebo (95% CI) 51·3 (43·2, 59·3) 58·69 (50·61, 66·67)  
  Unadjusted p valued <0·0001 <0·0001  
PASI100 response at Week24c, n/N (%) 82/184 (44·65%) 80/176 (45·56%) 5/183 (2·73%) 
  % difference vs placebo (95% CI) 42·2 (34·95, 49·650) 42·4 (34·85, 50·1)  
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  Unadjusted p valued <0·0001 <0·0001  
MDA response at Week24, n (%) 46 (18·89%) 62 (25·0%) 15 (6·1%) 
  % difference vs placebo (95% CI) 12·73 (7·0, 18·4) 18·99 (12·83, 25·0)  
  Unadjusted p valued <0·0001 <0·0001  
Patients meeting treatment-failure criteria (13 [5%] q4w, 12 [5%] q8w, and 17 [7%] placebo patients) were considered 
nonresponders for binary clinical endpoints and as having  no improvement from baseline for continuous clinical endpoints. After 
application of treatment failure rules, there were limited instances of patients with missing data (ACR20: 2 q8w, 1 placebo; 
DAS28-CRP: 2 q8w, 3 placebo;  IGA: 1 per group;  HAQ-DI: 2 q8w, 2 placebo; vdH-S: 5 q4w, 1 q8w, 1 placebo; PCS/MCS: 2 
q8w, 2 placebo; PASI: 1 per group; enthesitis/dactylitis resolution: 1 q8w, 1 placebo). Missing data were imputed as 
nonresponders for binary clinical endpoints; multiple imputation was used to impute missing data for continuous clinical 
endpoints assuming missing at random and using the predicted value from the Full Conditional Specification regression method 
(requiring 200 successful imputations) for any missing pattern. Each variable eligible for imputation was to be restricted to only 
impute within its possible range of values. Treatment differences for binary endpoints were assessed via Cochran-Mantel-
Haenszel test, and those for continuous endpoints were assessed via an analysis of covariance model. All models included 
treatment group, baseline non-biologic DMARD use (yes/no), most current CRP value prior to randomization (<2·0/≥2·0 
mg/dL), and baseline value as explanatory factors. Continuous radiographic endpoints were compared using an analysis of 
covariance test; missing data were assumed to be missing at random and were imputed using multiple imputation. The 95% CIs 
surrounding the % differences vs. placebo were determined based on the Wald statistic.  
a The FAS included all randomised and treated patients. 
b See Figure S1A. 
c Assessed in patients with ≥3% BSA affected by psoriasis and IGA score ≥2 at Week0. 
d Unadjusted (nominal) p values are not controlled for multiplicity and should be interpreted only as supportive.  
e Assessed in patients with HAQ-DI ≥0·35 at Week0. 
ACR20/50/70 – American College of Rheumatology 20/50/70% improvement, CI – confidence interval, DAS28-CRP – 28-joint 
Disease Activity Score based on C-reactive protein, FAS – full analysis set, HAQ-DI – Health Assessment Questionnaire-
Disability Index, IGA – Investigator’s Global Assessment, LS – least squares MCS – mental component summary, MDA – 
minimal disease activity, PASI/75/90/100 – Psoriasis Area and Severity Index 50/75/90/100% improvement, PCS – physical 
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component summary,  q4/8w – every 4/8 weeks, SF-36 – 36-item Short Form, PsA – psoriatic arthritis, US – United States, vdH-S 
– van der Heijde-Sharp 
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Table 3. Summary of Dactylitis and Enthesitis Results at Week 24 (FASa)  
 Guselkumab 100 mg  
Placebo 
 q4w q8w 
Major secondary endpoints controlled by US procedureb 
DISCOVER-1 + DISCOVER-2 Pooled 
Resolution of dactylitis, n/N (%)  101/159 (63·54%)  95/160 (59·4%)  65/154 (42·2%) 
 % difference vs placebo (95% CI) 21·3 (10·5, 32·0) 18·0 (7·4, 28·69)  
   US procedure-adjusted p value 0·0110 0·0301   
Resolution of enthesitis, n/N (%) 109/243 (44·95%)  114/230 (49·650%)  75/255 (29·4%) 
 % difference vs placebo (95% CI) 14·65 (6·4, 22·73) 20·1 (11·82, 28·5)  
   US procedure-adjusted p value 0·0301  0·0301   
Major secondary endpoints not controlled by US procedurec   
DISCOVER-1 + DISCOVER-2 Pooled 
Dactylitis score, LSmean (95% CI) change  -5·97 (-6·84, -5·11) -6·10 (-6·92, -5·27) -4·21 (-5·05, -3·36) 
  LSmean difference vs placebo (95% CI) -1·77 (-2·87, -0·66) -1·89 (-2·99, -0·79)  
  Unadjusted p value 0·0025 <0·0010020  
Enthesitis LEI score, LSmean (95% CI) change  -1·59 (-1·79, -1·38) -1·52 (-1·73, -1·31) -1·02 (-1·22, -0·82) 
  LSmean difference vs placebo (95% CI) -0·57 (-0·83, -0·31) -0·50 (-0·77, -0·23)  
 Unadjusted p value <0·0017 <0·0010003  
Dactylitis    
DISCOVER-1 resolution, n/N (%)  24/38 (63·2%) 32/49 (65·3%) 27/55 (49·1%) 
 % difference vs placebo (95% CI) 13·4 (-6·9, 33·7) 16·6 (-1·5, 34·8)  
 Unadjusted p value 0·212 0·088  
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Table 3. Summary of Dactylitis and Enthesitis Results at Week 24 (FASa)  
 Guselkumab 100 mg  
Placebo 
 q4w q8w 
DISCOVER-1 change from baseline, LSmean (95% 
CI) 
-5·82 (-7·82, -3·83) -6·11 (-7·81, -4·41) -4·30 (-5·96, -2·63) 
 LSmean difference vs placebo (95% CI) 
-1·53 (-4·00, 0·95) -1·82 (-4·12, 0·49) 
 
 Unadjusted p value 
0·225 0·121 
 
DISCOVER-2 resolution, n/N (%)  77/121 (63·6%) 63/111 (56·8%) 38/99 (38·4%) 
 % difference vs placebo (95% CI) 24·5 (11·8, 37·1) 18·7 (5·7, 31·7)  
 Unadjusted p value <0.001 0.007   
DISCOVER-2, change from baseline, LSmean (95% 
CI) 
-5·88 (-6·74, -5·01) -5·95 (-6·83, -5·08) -4·03 (-4·96, -3·10) 
 LSmean difference vs placebo (95% CI) 
-1·85 (-3·04, -0·65) -1·92 (-3·15, -0·70) 
 
 Unadjusted p value 
0·002 0·002 
 
Enthesitis LEI     
 DISCOVER-1 resolution, n/N (%) 35/73 (47·9%) 29/72 (40·3%) 21/77 (27·3%) 
 % difference vs placebo (95% CI) 19·8 (4·9, 34·6) 13·0 (-1·6, 27·5)  
 Unadjusted p value 0·013 0·094  
 DISCOVER-1 change from baseline, LSmean (95% 
CI) 
-1·75 (-2·13, -1·38) -1·35 (-1·72, -0·98) -1·01 (-1·37, -0·66) 
  LSmean difference vs placebo (95% CI) -0·74 (-1·24, -0·24) -0·33 (-0·83, 0·16)  
  Unadjusted p value 0·004 0·185  
 DISCOVER-2 resolution, n/N (%) 74/170 (43·5%) 85/158 (53·8%) 54/178 (30·3%) 
  % difference vs placebo (95% CI) 12·3 (2·6, 22·1) 23·3 (13·1, 33·5)  
 Unadjusted p value 0.017 <0.001  
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Table 3. Summary of Dactylitis and Enthesitis Results at Week 24 (FASa)  
 Guselkumab 100 mg  
Placebo 
 q4w q8w 
DISCOVER-2 change from baseline, LSmean (95% 
CI)  
-1·52 (-1·75, -1·29) -1·60 (-1·84, -1·37) -1·03 (-1·25, -0·81) 
 LSmean difference vs placebo (95% CI) -0·49 (-0·80, -0·19) -0·57 (-0·89, -0·26)  
 Unadjusted p value 0·002 <0·001  
See Table 2 for further details of statistical testing. 
a The FAS included all randomised and treated patients. 
b Per the preplanned statistical analysis plan, resolution of dactylitis and enthesitis data were combined across DISCOVER-1 and 
DISCOVER-2 as major secondary endpoints in the US testing procedure (See Figure S1A). 
c Unadjusted (nominal) p values are not controlled for multiplicity and should be interpreted only as supportive. 
CI – confidence interval, FAS – full analysis set, LEI – Leeds Enthesitis Index, LS – least squares, q4/8w – every 4/8 weeks, US – 
United States 
  663 
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Table 4. Summary of safety results through Week 24 (SAS) 
 Guselkumab 100 mg  
Placebo 
 q4w q8w Combined 
Number of patients  245 248 493 246 
Mean length of follow up (weeks) 23·8 23·9 23.9 24·0 
Mean number of administrations 5·9 5·9 5.9 5·9 
Patients with 1 or more AE, n (%)  113 (46·1%) 114 (46·0%) 227 (46·0%) 100 (40·71%) 
  AEs occurring in ≥3% of patients in any group (in alphabetical order) 
Alanine aminotransferase increased  25 (10·2%) 15 (6·0%) 40 (8·1%) 11 (4·5%) 
Aspartate aminotransferase increased 11 (4·5%) 14 (5·6%) 25 (5·1%) 6 (2·4%) 
  Bronchitis 10 (4·1%) 1 (0·4<1%) 11 (2·2%) 3 (1·2%) 
Nasopharyngitis 12 (4·95%) 10 (4·0%) 22 (4·5%) 9 (3·74%) 
Upper respiratory tract infection 12 (4·95%) 6 (2·4%) 18 (3·74%) 8 (3·3%) 
Patients with 1 or more SAE, n (%) 8 (3·3%)a 3 (1·2%)b  11 (2·2%) 7 (2·83%)c 
Patients with AE resulting in study drug d/c, n (%) 6 (2·4%)d 2 (0·81%)e  8 (1·62%) 4 (1·62%)f 
MACE, n (%) 1 (<10·4%) 0 1 (0·2<1%) 0 
Malignancy, n (%) 0 1 (0·4<1%) 1 (0·2<1%) 1 (0·4<1%) 
Patients with infectionsg, n (%) 49 (20·0%) 40 (16·1%)  89 (18·1%) 45 (18·3%)  
  Serious infections 3 (1·2%)  1 (<10·4%)  4 (0·81%) 1 (0·4<1%)  
Patients with injection-site reactions, n (%) 3 (1·2%)  3 (1·2%)  6 (1·2%) 1 (0·4<1%)  
Patients with suicidal ideation, n (%) 1 (0·4<1%)  0  1 (0·2<1%) 1 (0·4<1%)  
a 1 patient each with acute hepatitis B, blue toe syndrome, femur fracture, influenza pneumonia, ischaemic stroke, lower limb 
fracture/metal poisoning, oophoritis, osteoarthritis. 
b 1 patient each with ankle fracture, coronary artery disease, pyrexia. 
c 1 patient each with clear cell renal cell carcinoma, isoniazid-induced liver injury, inflammatory bowel disease (suspected), 
obesity, post-procedural fistula, tubulointerstitial nephritis, unstable angina. 
d 1 patient each with acute hepatitis B (de novo), allergic dermatitis, isoniazid-induced liver injury, ischaemic stroke, rhinovirus 
infection, and injection-site erythema/swelling/warmth. 
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Table 4. Summary of safety results through Week 24 (SAS) 
 Guselkumab 100 mg  
Placebo 
 q4w q8w Combined 
e 1 patient each with rash, malignant melanoma in situ. 
f 1 patient each with clear cell renal cell carcinoma, isoniazid-induced liver injury, inflammatory bowel disease, 
tubulointerstitial nephritis 
g AEs identified by investigators as infections 
AE – adverse event, d/c – discontinuation, MACE – major adverse cardiovascular event, q4/8w – every 4/8 weeks, SAE – 
serious adverse event, SAS – safety analysis set (treated patients) 
664 
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Figure 1. Patient disposition through Week 24. Two patients (1-guselkumab q4w, 1-placebo 
were randomized in error and never treated). CRP – C-reactive protein, q4/8w – every 4/8 weeks, 
TB – tuberculosis, W/D - withdrawal 
 
 
 
 
 
49 
 
 
  
 
 
50 
 
Figure 2. 
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Summary (282/300 words) 26 
Background: The interleukin-23/Th17 pathway is implicated in psoriatic arthritis pathogenesis. 27 
Guselkumab, an interleukin-23-inhibitor that specifically binds the IL23p19-subunit, 28 
significantly and safely improved psoriatic arthritis in a Phase-2 study. 29 
Methods: This Phase-3, double-blind, placebo-controlled study (118 sites in 13 countries) 30 
enrolled biologic-naïve patients with active psoriatic arthritis (≥5 swollen, ≥5 tender joints, 31 
C-reactive-protein ≥0·6 mg/dL) despite standard therapies. Patients were randomised (1:1:1; 32 
computer-generated permuted blocks; stratified by baseline disease-modifying antirheumatic 33 
drug use and C-reactive-protein) to subcutaneous guselkumab 100 mg every-4-weeks (q4w); 34 
guselkumab 100 mg at Weeks 0, 4, every-8-weeks (q8w); or placebo. The primary endpoint was 35 
ACR20 response at Week24 among randomized and treated patients. Clinicaltrials.gov 36 
identifier-NCT03158285 (active-not recruiting). 37 
Findings: From 07/13/2017–03/06/2019, 739 randomised patients received guselkumab q4w 38 
(N=245), q8w (N=248), or placebo (N=246); 716 patients continued treatment through Week24. 39 
Significantly greater proportions of guselkumab q4w- (156 [64%] of 245; 95% confidence 40 
interval: 57%, 70%) and q8w- (159 [64%] of 248; 95% confidence interval: 58%, 70%) than 41 
placebo- (81 [33%] of 246; 95% confidence interval: 27%, 39%) treated patients achieved 42 
Week24 ACR20 response (% differences [95% confidence intervals]: 31 (22, 39) and 31 (23, 43 
40), respectively; both p<0·0001). Through Week24, serious adverse events, and specifically 44 
serious infections, occurred in eight (3%) and three (1%) of 245 patients receiving guselkumab 45 
q4w, three (1%) and one (<1%) of 248 receiving guselkumab q8w, and seven (3%) and one 46 
(<1%) of 246 receiving placebo, respectively. No deaths occurred. 47 
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Interpretation: Guselkumab, a human monoclonal antibody that specifically inhibits 48 
interleukin-23 by binding the cytokine’s p19-subunit, was efficacious and well tolerated in 49 
patients with active psoriatic arthritis who were biologic naive. These data support the further 50 
development of guselkumab for treating psoriatic arthritis.  51 
Funding: Janssen Research & Development, LLC  52 
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Panel - Research in context 53 
Evidence before this study – Current literature indicates that interleukin-23 is instrumental in 54 
driving the chronic inflammation associated with several immune-mediated diseases, including 55 
psoriasis and psoriatic arthritis. Guselkumab is a high-affinity, anti-interleukin-23 human 56 
monoclonal antibody that specifically bind’s the cytokine’s p19-subunit and is approved to treat 57 
moderate-to-severe psoriasis. In a Phase-2 study, selective blockade of interleukin-23 by 58 
guselkumab significantly improved signs and symptoms of active psoriatic arthritis and was well 59 
tolerated during 1 year of exposure.  60 
Added value of this study – Results of this pivotal study, the larger of two comprising the first 61 
Phase-3 program investigating a novel mechanism of action to treat psoriatic arthritis, confirm 62 
that targeting the p19-subunit of interleukin-23 effectively treats the diverse domain 63 
manifestations of psoriatic arthritis. Specifically, in patients with active disease despite non-64 
biologic disease-modifying antirheumatic, apremilast, and/or nonsteroidal anti-inflammatory 65 
drug treatment, but no prior exposure to biologics, subcutaneous guselkumab 100 mg 66 
significantly improved joint symptoms, dactylitis, enthesitis, psoriasis, physical function, and 67 
quality of life when administered every 4 or 8 weeks. Progression of structural damage through 68 
Week24 was significantly lower with guselkumab q4w, and numerically lower with q8w, dosing 69 
vs. placebo, providing initial evidence of inhibition of radiographic progression by an 70 
interleukin-23 inhibitor that target its p19-subunit. The guselkumab safety profile in psoriatic 71 
arthritis patients was comparable to profiles observed in placebo-treated psoriatic arthritis 72 
patients and guselkumab-treated patients with psoriasis.  73 
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Implications of all the available evidence – Consistent with previous findings of a proof-of-74 
concept study confirming that interleukin-23 plays a critical role in the pathogenesis of psoriatic 75 
arthritis, these Phase-3 trial data provide pivotal evidence that guselkumab offers a novel 76 
mechanism of action to treat the diverse clinical manifestations of psoriatic arthritis and inhibit 77 
structural damage progression.  78 
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INTRODUCTION 79 
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with peripheral joint 80 
inflammation, enthesitis, dactylitis, axial disease, and cutaneous and nail involvement, all of 81 
which can significantly limit physical function and impair quality of life. While the introduction 82 
of biologic (e.g., tumor necrosis factor-α inhibitors [TNFi], ustekinumab, interleukin [IL]-17A 83 
inhibitors, abatacept) and oral (e.g., apremilast, tofacitinib) agents has increased the extent and 84 
duration of achievable clinical responses, new therapies are needed to treat the diverse 85 
manifestations of PsA while maintaining a favorable risk-benefit profile.1 86 
The origins of the varying clinical manifestations of PsA remain under study. The IL-23/T-helper 87 
cell 17 (Th17) pathway – via downstream IL-17 expression - appears critical to skin 88 
manifestations. IL-23 can also induce IL-22, a cytokine implicated in enthesitis and bone 89 
formation,2 and, in part via IL-17A and TNF induction, elicit the joint symptoms and damage 90 
that are hallmarks of PsA. IL-23 is a heterodimer formed by pairing p19- and p40-subunits, the 91 
latter of which is shared with IL-12. Although IL-12 and IL-23 share the p40-subunit, they also 92 
encompass unique p35- (for IL-12) and p19- (for IL-23) subunits.3,4 Whereas IL-23 has been 93 
determined to be a predominant promoter of autoimmune-mediated articular inflammation, IL-12 94 
more likely facilitates protection from autoimmune inflammation and T-cell exhaustion.4-7  The 95 
divergent roles of these closely related cytokines are highlighted by differential skin effects, 96 
whereby abnormal differentiation of keratinocytes is triggered by IL-23, but not IL-12,6 and 97 
differing roles in the body’s response to bacterial and viral infections, as well as tumour control 98 
via their regulation of T-cell function.5 Targeting the p19-subunit of IL-23, and thus sparing IL-99 
12, has demonstrated robust efficacy in psoriasis,7-10 suggesting a prominent upstream position in 100 
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the inflammatory hierarchy across the psoriatic disease spectrum, which thereby merits 101 
evaluation of selective IL-23 inhibition via IL23-p19 binding in PsA.  102 
Guselkumab (Janssen Biotech, Inc., Horsham, PA, USA), a high-affinity, human monoclonal 103 
antibody that binds specifically to the p19-subunit of IL-23, is approved to treat patients with 104 
moderate-to-severe psoriasis who are candidates for systemic and/or phototherapy. In a 105 
randomised, placebo-controlled, Phase-2 study evaluating subcutaneous guselkumab 100 mg at 106 
Weeks 0, 4 and every 8 weeks (q8w) in 149 patients with active PsA, including ≥3% body 107 
surface area (BSA) of psoriasis, guselkumab demonstrated efficacy across all endpoints related 108 
to joint signs and symptoms, physical function, skin disease, enthesitis, dactylitis, and health-109 
related quality of life.11   110 
Herein, we report 24-week results from one of two Phase-3 trials, i.e., DISCOVER-2, conducted 111 
to evaluate guselkumab in biologic-naïve patients with active PsA. DISCOVER-2 evaluations 112 
included joint and skin manifestations, as well as structural damage. Results from the other 113 
registrational trial of guselkumab in PsA (DISCOVER-1), which aimed to enroll patients with a 114 
broader range of baseline levels of disease activity, some of whom were previously treated with 115 
one or two TNFi, are reported elsewhere (Lancet.org doi.xxxx).  116 
117 
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METHODS 118 
Study design 119 
This Phase-3, randomised, double-blind, placebo-controlled, multicenter, 3-arm study of 120 
guselkumab in patients with active PsA, who were biologic-naïve and demonstrated inadequate 121 
response to standard therapies (non-biologic disease-modifying antirheumatic drugs [DMARDs], 122 
apremilast, and/or nonsteroidal anti-inflammatory drugs [NSAIDs]), was conducted at 118 sites 123 
worldwide (see Online Supplement). Screening began 07/13/2017; the final Week-24 visit 124 
occurred on 02/25/2019. The trial design includes a 6-week screening period; a 100-week 125 
treatment phase, with a placebo-controlled period from Week0–Week24 and an active treatment 126 
period from Week24–Week100; and 12-weeks of safety follow-up after the last administration of 127 
study agent. At Week16, all patients with <5% improvement in both swollen and tender joint 128 
counts were eligible for early escape, in which the investigator could initiate or increase the dose 129 
of NSAIDs or other analgesics (up to the regional marketed dose approved), oral corticosteroids 130 
(≤10 mg/day of prednisone or equivalent dose), or non-biologic DMARDs (limited to 131 
methotrexate ≤25 mg/week, sulfasalazine ≤3g/day, hydroxychloroquine ≤400 mg/day, or 132 
leflunomide ≤20 mg/day). Study results through Week24 are reported. This trial (NCT03158285) 133 
is being conducted per Declaration of Helsinki and Good Clinical Practice guidelines. The 134 
protocol (available at Lancet.org) was approved by each site’s governing ethical body.  135 
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Participants 136 
Approximately 684 eligible patients were planned for this study. Adults with PsA for ≥6 months, 137 
fulfilling the Classification Criteria for Psoriatic Arthritis12 and with ≥5 tender and ≥5 swollen 138 
joints; C-reactive protein (CRP) ≥0·6 mg/dL; current or documented history of psoriasis; and 139 
either inadequate response to, or intolerance of, standard non-biologic treatment were eligible. 140 
Standard treatment included ≥3 months of non-biologic DMARDs, ≥4 months of apremilast at 141 
the approved dose (if discontinued >4 weeks before receiving study agent), or ≥4 weeks of 142 
NSAIDs for PsA. Previous exposure to biologic agents or Janus kinase inhibitors precluded 143 
participation. Patients were permitted, but not required, to continue stable use of selected non-144 
biologic DMARDs (limited to those allowed for early escape), and NSAIDs/other analgesics. 145 
Only one DMARD was permitted through Week52. Patients also had to meet screening criteria 146 
for laboratory evaluations and tuberculosis (TB) history/testing/treatment (for latent TB). Full 147 
inclusion and exclusion criteria, and further details of permitted and prohibited therapies, are 148 
included in the protocol (Lancet.org doi.xxxx). All patients provided written informed consent.  149 
Randomisation and masking 150 
At Week0, patients were centrally randomised using an interactive web response system (with 151 
computer-generated permuted-block randomisation stratified by baseline non-biologic DMARD 152 
use [yes/no] and the most recent high-sensitivity serum CRP value prior to randomization 153 
[<2·0/≥2·0 mg/dL]) in a 1:1:1 ratio to receive guselkumab 100 mg every 4 weeks (q4w); 154 
guselkumab 100 mg at Week0, Week4, and every 8 weeks (q8w); or placebo. Blinding was 155 
accomplished as reported for DISCOVER-1 (Lancet.org doi.xxxx). 156 
 157 
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Procedures  158 
Guselkumab was administered as a 100-mg subcutaneous injection at Week0, Week4, and then 159 
q4w or q8w. Dose selection for DISCOVER-2 was as described for DISCOVER-1 (Lancet.org 160 
doi.xxxx). Clinical efficacy and safety assessments were performed at screening, baseline, 161 
Week2, Week4, and q4w through Week24. An independent joint assessor evaluated 66 joints for 162 
swelling, 68 joints for tenderness, and determined the presence/severity of enthesitis (Leeds 163 
Enthesitis Index [LEI]) and dactylitis. Dactylitis severity for each digit was scored as 0–no 164 
dactylitis, 1–mild dactylitis, 2–moderate dactylitis, or 3–severe dactylitis (total score 0–60). 165 
Serum pharmacokinetic and immunogenicity assessments are as reported for DISCOVER-1 166 
(Lancet.org doi.xxxx). As well, details of joint (American College of Rheumatology [ACR] 167 
response, 28-joint Disease Activity Score incorporating CRP [DAS28-CRP]), skin 168 
(Investigator’s Global Assessment of psoriasis [IGA], Psoriasis Area and Severity Index 169 
[PASI]), physical function (Health Assessment Questionnaire-Disability Index [HAQ-DI]), 170 
health-related quality of life (36-item Short-Form [SF-36] Health Survey), and safety (adverse 171 
events [AEs], routine haematology and chemistry assessment, electronic Columbia-Suicide 172 
Severity Rating Scale [eC-SSRS] questionnaires) assessments are as reported for DISCOVER-1 173 
(Lancet.org doi.xxxx). 174 
In DISCOVER-2, single radiographs of the hands (posteroanterior) and feet (anteroposterior) 175 
were obtained at screening and Week24. Radiographs were evaluated independently by two 176 
central readers (blinded to order of radiographs and clinical data), with the van der Heijde-Sharp 177 
(vdH-S) score modified for PsA (distal interphalangeal joints of hands added).13 Adjudication 178 
was employed as mandated by primary reader disagreement. The total PsA-modified vdH-S 179 
score (0–528) sums the joint erosion score (0–320; 0–no erosions, 5–extensive loss of bone from 180 
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>50% of the articulating bone) and the joint space narrowing (JSN) score (0–208; 0–no JSN, 4–181 
complete loss of joint space, bony ankylosis, or complete luxation). The average score of the two 182 
readers was employed in analyses. 183 
Outcomes 184 
The primary endpoint was the ACR20 response rate at Week24. Major secondary endpoints 185 
included ACR50 and ACR70 responses, changes from baseline in DAS28-CRP scores, IGA skin 186 
response (score=0/1 and ≥2-grade improvement from baseline) among patients with ≥3% BSA of 187 
psoriasis and IGA≥2 (mild-to-severe psoriasis) at baseline, changes from baseline in HAQ-DI 188 
and PsA-modified vdH-S scores, changes from baseline in, and resolution of, enthesitis and 189 
dactylitis pooled across DISCOVER-1&2 (Statistical analyses), changes in the SF-36 190 
physical/mental component summary (PCS/MCS) scores, all at Week24, and ACR20/ACR50 191 
responses at Week16. Other selected key secondary outcomes included clinically meaningful 192 
improvement (≥0.35) in HAQ-DI scores in patients with baseline HAQ-DI scores ≥0·35, 193 
≥75/90/100% improvement in the PASI (PASI75/PASI90/PASI100) in patients with mild-to-194 
severe psoriasis at baseline, and minimal disease activity (MDA; see Lancet.org doi.xxxx), all at 195 
Week24. Safety outcomes were as reported for DISCOVER-1 (Lancet.org doi.xxxx).   196 
Statistical analyses 197 
Assuming Week24 ACR20 response rates of 45% with guselkumab versus 25% with placebo, 198 
684 patients (228/treatment group) were required to provide ~99% statistical power (α=0·05; 199 
2-sided). With 684 patients, the study was estimated to have 90% power to detect a treatment 200 
difference in change from baseline in total PsA-modified vdH-S scores, assuming mean changes 201 
from baseline at Week24 of 0·9 and 0·3, respectively, in placebo- and across all guselkumab-202 
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treated patients and a standard deviation of 2·5 for each treatment. Strategies employed to control 203 
the overall Type 1 error rate are described below. 204 
Efficacy analyses through Week24 included all randomised patients who received ≥1 205 
administration of study treatment and were conducted according to assigned treatment groups 206 
(full analysis set). Treatment differences for binary endpoints were assessed via a Cochran-207 
Mantel-Haenszel test; those for continuous endpoints employed an analysis of covariance model.  208 
To increase sample size, endpoints related to enthesitis and dactylitis among the smaller number 209 
of patients with those conditions at baseline were prespecified to be tested by pooling data from 210 
this study with those from DISCOVER-1 (Lancet.org doi.xxxx). Results of these pooled analyses 211 
are presented herein. 212 
Owing to differences in health authority requirements for multiplicity control between the United 213 
States (US) and other countries, two graphical testing procedures were prespecified to control 214 
overall Type I error at α=0·05 (2-sided). For both approaches, the primary endpoint (ACR20 215 
response at Week24) was first tested for the q4w group and then for the q8w group (each at 0·05 216 
level). The first graphical procedure (Figure S1A) controlled the overall Type 1 error rate across 217 
both dosing regimens at the 0·05 level for the primary and the following major secondary 218 
endpoints at Week24: IGA skin response among patients with mild-to-severe psoriasis; changes 219 
in HAQ-DI, PsA-modified vdH-S, and SF-36 PCS scores; resolution of dactylitis and enthesitis 220 
among patients with the respective condition at baseline pooled across both DISCOVER trials, 221 
and changes in SF-36 MCS scores. Results of this testing procedure are presented in the main 222 
manuscript text and those from the second graphical procedure (Figure S1B), which controlled 223 
the overall Type 1 error rate for each dosing regimen at the 0·05 level for all major secondary 224 
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endpoints, except changes from baseline in enthesitis and dactylitis scores at Week24, with two 225 
parallel procedures, are provided online (Table S1). For endpoints not controlled for multiplicity, 226 
unadjusted (nominal) p values provided should be interpreted only as supportive. 227 
Data handling rules were applied to all clinical efficacy analyses. Patients who met treatment-228 
failure criteria (discontinued study agent, terminated study participation, initiated or increased 229 
DMARD or oral corticosteroid doses, initiated protocol-prohibited PsA treatment) were 230 
considered nonresponders for binary endpoints and as having no improvement from baseline for 231 
continuous endpoints. Missing data were imputed as nonresponders for binary endpoints and 232 
using multiple imputation for continuous endpoints. For radiographic endpoints, treatment failure 233 
rules were not applied, and missing data (five in guselkumab q4w group, one in guselkumab q8w 234 
group, one in placebo group) were imputed using multiple imputation.  235 
An independent data monitoring committee examined data on an ongoing basis through the 236 
Week24 database lock to ensure the safety of the study participants. Statistical analyses were 237 
performed using SAS version 9.4 with SAS/STAT version 14.2 (SAS Institute, Inc., Cary, NC, 238 
USA). This active (not recruiting) study was registered in Clinicaltrials.gov (NCT03158285). 239 
Role of the funding source 240 
Janssen Research and Development, LLC funded this trial. All authors, including employees of 241 
Janssen (APK, ECH, XLX, SS, PA, BZ, YZ), were involved in data collection, analysis, and/or 242 
interpretation; trial design; manuscript preparation; and the decision to submit the paper for 243 
publication. Janssen provided funding to a professional medical writer who assisted with 244 
manuscript preparation and submission. The corresponding author (PJM) had full access to all 245 
study data and final responsibility to submit for publication.  246 
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RESULTS 247 
From 1,153 screened patients, 741 were randomised. Patients failed screening most often for 248 
serum CRP levels <0·6 mg/dL. Overall, 739 randomised patients were treated with guselkumab 249 
q4w (N=245), guselkumab q8w (N=248), or placebo (N=246) and included in the full analysis 250 
set. At Week16, 12 (5%) of 245 guselkumab q4w-, 13 (5%) of 248 guselkumab q8w-, and 38 251 
(15%) of 246 placebo-treated patients had <5% improvement in both tender and swollen joint 252 
counts and qualified for early escape, of which seven (3%) of 245 guselkumab q4w-, six (2%) of 253 
248 guselkumab q8w-, and 14 (6%) of 246 placebo-treated patients initiated or increased the 254 
dose of NSAIDs, oral corticosteroids, and/or permitted non-biologic DMARDs. Overall,  23 255 
(3%) of 739 treated patients discontinued study agent, most commonly due to AEs, resulting in 256 
robust patient retention through Week24 (Figure 1).  257 
Baseline characteristics were generally well balanced across randomised groups. Modest 258 
numerical differences were observed between the guselkumab and placebo groups for the 259 
proportions of males, severity of psoriasis assessed by the PASI score, and presence of dactylitis 260 
and enthesitis at study outset. Background medication use was consistent across randomised 261 
treatment groups; among the 739 treated patients, 512 (69%) were receiving non-biologic 262 
DMARDs, including 443 (60%) receiving MTX, 145 (20%) were receiving oral corticosteroids 263 
for PsA, and 504 (68%) reported NSAID use at baseline (Table 1). 264 
Major protocol deviations were evenly distributed between guselkumab- (35 [7%] of 493) and 265 
placebo- (23 [9%] of 246) treated patients. Overall, 11 patients (five guselkumab, six placebo) 266 
entered the study without satisfying all criteria, six (four guselkumab, two placebo) received the 267 
incorrect treatment/dose), six (three guselkumab, three placebo) received a disallowed 268 
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medication, and one (guselkumab) met a withdrawal criterion but was not withdrawn. No 269 
deviation was considered to impact overall results. 270 
For the study’s primary endpoint, significantly greater proportions of patients in the guselkumab 271 
q4w (156 [64%] of 245; 95% confidence interval [CI]: 57%, 70%) and q8w (159 [64%] of 248; 272 
95% CI: 58%, 70%) groups than in the placebo group (81 [33%] of 246; 95% CI: 27%, 39%) 273 
groups achieved an ACR20 response at Week24 (% differences [95% confidence interval (CIs): 274 
31 [22, 39] and 31 [23, 40], respectively; both p<0·0001; Table 2). Results of all prespecified 275 
sensitivity analyses were consistent with the primary analysis (data on file).  276 
A consistent treatment benefit was observed for the primary efficacy endpoint for both 277 
guselkumab dosing regimens across patient subgroups defined by demography, baseline disease 278 
characteristics, and prior and baseline medication use. In particular, ACR20 response at Week24 279 
was consistent in the subgroup of patients with MTX use at baseline (q4w: 92 [63%] of 146 and 280 
q8w: 85 [60%] of 141), 281 
With both guselkumab dosing regimens, more patients achieved ACR20 response vs. placebo by 282 
Week4 (following one injection of guselkumab); response rates continued to increase through 283 
Week24 (Figure 2A).  ACR50 and ACR70 response rates were also consistently higher with both 284 
guselkumab dosing regimens vs. placebo (Figures 2B, 2C). Higher rates of ACR20 response at 285 
Week16, ACR50 response at Week16 and Week24, and ACR70 response at Week24 were 286 
observed among guselkumab q4w- and q8w-treated than placebo-treated patients. Further, 287 
greater improvements in DAS28-CRP scores at Week24 were observed with guselkumab q4w 288 
(LS mean change: -1·62) and q8w (-1·59) vs. placebo (-0·97; Table 2). 289 
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Among DISCOVER-1 (Lancet.org doi.xxxx) and DISCOVER-2 patients with the respective 290 
manifestations at baseline, dactylitis resolved at Week24 in significantly higher proportions of 291 
guselkumab q4w- (101 [64%] of 159) and q8w- (95 [59%] of 160) than placebo- (65 [42%] of 292 
154) treated patients (p=0·0110 and p=0·0301, respectively). Resolution of enthesitis was also 293 
observed in significantly higher proportions of guselkumab q4w- (109 [45%] of 243) and q8w- 294 
(114 [50%] of 230) than placebo- (75 [29%] of 255) treated patients (both p=0·0301) when 295 
combined across both trials. Improvements from baseline in the enthesitis LEI and dactylitis 296 
scores at Week24 were also numerically greater with both guselkumab dosing regimens than 297 
placebo when pooled across DISCOVER-1 and DISCOVER-2 (Table 3), and consistent trends 298 
were observed in the individual trials (Table S2). 299 
Patients treated with guselkumab q4w demonstrated significantly less progression of structural 300 
damage, as reflected by smaller changes from baseline in the PsA-modified vdH-S score at 301 
Week24, than placebo-treated patients (LS mean [95% CI]: 0·29 [-0·05, 0·63] vs. 0·95 [0·61, 302 
1·29], respectively; p=0·0110). Guselkumab administered q8w resulted in numerically less 303 
radiographic progression (LS mean [95% CI]: 0·52 [0·18, 0·86]) than placebo, but the treatment 304 
difference did not achieve statistical significance (p=0·07; Table 2). A probability plot of 305 
changes in modified vdH-S scores from baseline at Week24 is provided in Figure S2. 306 
In patients with mild-to-severe psoriasis at baseline, guselkumab q4w and q8w significantly 307 
improved skin disease, as assessed by IGA response rates, at Week24 vs. placebo (126 [68%] of 308 
184 and 124 [70%] of 176, respectively vs. 35 [19%] of 183; both p<0·0001; Table 2, Figure 309 
2D). PASI75, PASI90, and PASI100 response rates were also higher among guselkumab- than 310 
placebo-treated patients (Table 2).  311 
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Guselkumab q4w and q8w significantly improved HAQ-DI scores from baseline at Week24 vs. 312 
placebo (LSmean [95% CI] changes: -0·40 [-0·46, -0·34] and -0·37 [-0·43, -0·31], respectively, 313 
vs. -0·13 [-0·19, -0·07]; both p<0·0001). The proportions of patients with improvement in the 314 
HAQ-DI score ≥0·35 at Week24, among those with baseline HAQ-DI ≥0·35, also indicated that 315 
guselkumab q4w (128 [56%] of 228) and q8w (114 [50%] of 228) improved physical function to 316 
a greater extent than placebo (74 [31%] of 236; Table 2). 317 
Patients started the study with impaired health-related quality-of-life as assessed by mean SF-36 318 
PCS (32·4–33·3) and MCS (47·2–48·4) scores (US general population norm=50.0). Significant 319 
improvements in SF-36 PCS scores from baseline at Week24 were demonstrated by guselkumab  320 
q4w and q8w, respectively, vs. placebo (LSmean changes: 7·04 and 7·39 vs. 3·42; both 321 
p=0·0110). Numerical improvements in SF-36 MCS scores (4·22 and 4·17 vs. 2·14; both 322 
p=0·07) were also observed for both guselkumab dosing regimens vs. placebo; although the 323 
lower bounds of the 95% CIs of the differences from placebo exceeded 0, differences were not 324 
significant after multiplicity adjustment (Table 2). At Week24, MDA was achieved by 46 (19%) 325 
of 245 and 62 (25%) of 248 patients receiving guselkumab q4w and q8w, respectively, vs. 15 326 
(6%) of 246 placebo-treated patients (Table 2).  327 
An overview of guselkumab pharmacokinetic and immunogenicity findings can be found in the 328 
Online Supplement. 329 
Guselkumab was generally well-tolerated. Through Week24, AEs were reported by 113 (46%) of 330 
245, 114 (46%) of 248, and 100 (41%) of 246 patients receiving guselkumab q4w, guselkumab 331 
q8w, and placebo, respectively. Serious AEs (SAEs) were reported by eight (3%) of 245, three 332 
(1%) of 248, and seven (3%) of 246 patients, and AEs led to discontinuation of study agent for 333 
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six (2%) of 245, two (1%) of 248, and four (2%) of 246 patients receiving guselkumab q4w, 334 
guselkumab q8w, and placebo, respectively (Table 4).  335 
The AEs reported by ≥3% of patients in any treatment group were infections (upper respiratory 336 
tract infection, nasopharyngitis, bronchitis) and laboratory investigations (alanine 337 
aminotransferase [ALT] increased, aspartate aminotransferase [AST] increased; Table 4). 338 
Serious infections occurred in three (1%) of 245 patients receiving guselkumab q4w (acute 339 
hepatitis B [de novo], influenza pneumonia, oophoritis), one (<1%) of 248 patients receiving 340 
guselkumab q8w (pyrexia [likely of urinary origin]), and one (<1%) of 246 placebo-treated 341 
patients (post-procedural fistula). No Candida or opportunistic infections, or cases of active TB, 342 
occurred through Week24. No AEs of inflammatory bowel disease were reported in guselkumab-343 
treated patients, whereas there was one suspected case in the placebo group through Week24.  344 
No deaths were reported through Week24. One patient in each of the guselkumab q4w (at Week2 345 
only) and placebo (pre-existing and at Week12) groups experienced suicidal ideation (Level 1 – 346 
wish to be dead); no patient reported suicidal or self-injurious behavior without suicidal intent 347 
through Week24. Two patients were diagnosed with a malignancy through Week24 (guselkumab 348 
q8w: melanoma in situ at Week4; placebo: clear-cell renal cell carcinoma at Week12). One 349 
patient had a major acute cardiovascular event: a 58-year-old female with a history of 350 
hypertension, hyperlipidemia, and diabetes and who was receiving guselkumab 100 mg q4w had 351 
an ischaemic stroke at Week20. The patient recovered, and study drug was discontinued.  352 
Two patients demonstrated maximum National Cancer Institute Common Terminology Criteria 353 
for AEs (NCI-CTCAE) Grade-3 or 4 neutropenia, one in the placebo group (Grade-3 [<1·0–0·5 x 354 
109/L] at Week 8 only) and one in the guselkumab q4w group (did not recur upon retest the 355 
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following week, not associated with infections or study drug interruptions). No other NCI-356 
CTCAE Grade-3 or higher hematology abnormalities were observed in guselkumab-treated 357 
patients, except a case of anemia in one guselkumab q8w-treated patient (Grade-3 hemoglobin 358 
[<80·0 g/L] of 69 g/L at Week16 only). 359 
The proportions of patients with increased ALT or AST levels reported as AEs appeared slightly 360 
higher in the guselkumab than placebo groups (Table 4). The overall incidences of maximum 361 
NCI-CTCAE Grade-2 (>3.0–5.0 x upper limit of normal [ULN]) ALT and AST increases were 362 
low and slightly more common in guselkumab- (nine [2%] and 11 [2%] of 490 patients, 363 
respectively) than placebo- (four [2%] and none of 246 patients, respectively) treated patients. 364 
Maximum NCI-CTCAE Grade-3 (>5·0–20·0 x ULN) or Grade-4 (>20·0 x ULN) ALT values 365 
were observed in four (2%) of 243 patients receiving guselkumab q4w (all Grade-3), three (1%) 366 
of 247 patients receiving guselkumab q8w (all Grade-3), and two (1%) of 246 placebo-treated 367 
patients (one patient each with Grade-3 and Grade-4 values). For AST, maximum NCI-CTCAE 368 
Grade-3 (>5·0–20·0 x ULN) or Grade-4 (>20·0 x ULN) values were observed in five (2%) of 369 
243 patients receiving guselkumab q4w (all Grade-3), one (<1%) of 247 patients receiving 370 
guselkumab q8w (Grade-3), and two (1%) of 246 placebo-treated patients (all Grade-3). These 371 
laboratory abnormalities resulted in study drug discontinuation in one placebo-treated patient 372 
(Week8 ALT/AST of 1053/665 U/L related to serious isoniazid-induced hepatitis that resolved 373 
by Week12) and two patients receiving guselkumab q4w (one with Week4 ALT/AST of 374 
479/484 U/L related to non-serious AE of isoniazid-induced hepatitis that resolved by Week16 375 
and one with Week20 ALT/AST of 373/238 U/L related to an SAE of acute hepatitis B with no 376 
clinically significant increase in bilirubin; AEs were resolving at the last contact).   377 
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DISCUSSION  378 
Results of the Phase-3, multicenter, randomised, double-blind, placebo-controlled, DISCOVER-379 
2 study through Week24 indicate that guselkumab, a selective IL-23 inhibitor that binds the 380 
cytokine’s p19-subunit, effected robust improvements in signs and symptoms of joint disease in 381 
patients with PsA. The study met its primary endpoint for both guselkumab 100 mg q4w and 382 
q8w, with 64% and 64% of these patients, respectively, achieving an ACR20 response at 383 
Week24, compared with 33% of placebo-treated patients. Similarly, ACR50 and ACR70 384 
response rates demonstrated that treatment with guselkumab results in clinically meaningful 385 
reductions in the joint signs and symptoms of PsA. Improvement occurred at early timepoints 386 
and increased over time through Week24. 387 
Guselkumab, whether administered q4w or q8w, also elicited significant improvements in skin 388 
psoriasis, physical function, and health-related quality of life, all of which significantly impact 389 
mental health, work productivity, and the economic burden of PsA.14,15 Of particular note, >60% 390 
of guselkumab-treated patients achieved PASI90 and 45% achieved PASI100 responses at 391 
Week24. These findings are consistent with the established efficacy of guselkumab in treating 392 
moderate-to-severe plaque psoriasis.7,9,10  Guselkumab q4w inhibited progression of structural 393 
damage vs. placebo at Week24, based on changes in the PsA-modified vdH-S score. 394 
Guselkumab q8w dosing also reduced structural damage progression, but the difference from 395 
placebo was not statistically significant. This observation could derive from differences in total 396 
guselkumab exposure between q4w and q8w dosing from Weeks0-24. Radiographic data being 397 
collected through 1 year will provide additional data with which to evaluate the ability of the 398 
q8w dosing regimen to limit progression of structural damage. 399 
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Inflammation of periarticular tissues such as dactylitis and enthesitis, is a hallmark of PsA that 400 
can present a treatment challenge.16  IL-23 is essential for both activating Th17 cells, which 401 
produce IL-17A, and maintaining IL-17A production thereafter.2 IL-23 also regulates innate cells 402 
(e.g., γδ T, natural killer T, and innate lymphoid cell subsets), which are predominantly located 403 
in non-lymphoid tissue and, upon stimulation by IL-23, produce pro-inflammatory cytokines (IL-404 
17, IL-22, and interferon-γ), thereby inducing local tissue inflammation.17-20 Given that 405 
guselkumab 100 mg q8w has been shown to decrease serum IL-17A concentrations of PsA 406 
patients to levels observed in healthy controls by Week16,21 it is not unexpected that both 407 
guselkumab regimens afforded significantly higher proportions of patients with clinically 408 
resolved dactylitis and enthesitis at Week24 when data were pooled across DISCOVER-1 and 409 
DISCOVER-2.  410 
As a downstream effector cytokine of IL-23, IL-17A has been implicated mechanistically in both 411 
inflammation and bone remodeling in a murine rheumatoid arthritis model by stimulating 412 
osteoclastogenesis; promoting bone resorption in fetal mouse long bones; and inducing 413 
expression of the receptor activator of nuclear factor kappa-B-ligand, an osteoclast 414 
differentiation factor, in osteoclast-supporting cells.22 IL-23 can also induce IL-22, a cytokine 415 
implicated in bone formation.2 Because IL-23 regulates several effector cytokines that are 416 
thought to contribute to PsA disease pathology, inhibition of multiple effector cytokines through 417 
IL-23 targeting may provide more effective modulation of these processes than single cytokine 418 
inhibition.    419 
Guselkumab 100 mg was generally well tolerated in this PsA population, with no clinically 420 
meaningful differences between q4w and q8w dosing through Week24. No Candida or 421 
opportunistic infections or cases of active TB occurred. One suspected case of inflammatory 422 
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bowel disease was reported in a placebo-treated patient. There was no apparent association 423 
between the development of antibodies to guselkumab and the occurrence of injection-site 424 
reactions (see Online Supplement). The overall safety profile was generally consistent with that 425 
reported for patients with psoriasis.7,9,23 Specifically, guselkumab 100 mg q8w demonstrated a 426 
stable safety profile through 100 weeks of treatment, with no safety signals with regard to serious 427 
infection, malignancy, MACE, or suicidality, in an analysis of data from more than 1,800 428 
patients enrolled in two Phase-3 psoriasis studies.23 Further, in >800 patients with psoriasis who 429 
participated in the VOYAGE-1 study, no new safety signals were observed through up to 4 years 430 
of guselkumab 100 mg when given q8w.24   431 
The biologic-naïve DISCOVER-2 patients presented with an average of 12–13 swollen and 20–432 
22 tender joints, along with substantial systemic inflammation (median serum CRP: 1·2–433 
1·3 mg/dL), possibly limiting the applicability of findings to patients with less active disease. 434 
The relatively high placebo response rates observed for joint (ACR20-33%) and skin (IGA-19%) 435 
outcomes may also affect data interpretation. However, these response rates are consistent with 436 
other recently reported findings in biologic-naïve PsA populations,25,26 and likely reflect higher 437 
expectations for efficacy as more potent therapies have become available for PsA. It will be 438 
important to evaluate whether the favourable responses and safety profile through Week24 are 439 
maintained; such data are being collected throughout this 2-year study. 440 
Thus, guselkumab was well tolerated and demonstrated robust efficacy in DISCOVER-2 across 441 
clinical domains crucial to achieving PsA remission (e.g., synovitis, enthesitis, dactylitis, 442 
psoriasis), including reducing structural damage progression.27 By binding to IL-23’s p19-443 
subunit, but not the p40-subunit it shares with IL-12, guselkumab targets the key upstream 444 
regulatory cytokine responsible for the Th17 pathway implicated in PsA, thereby providing a 445 
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targeted yet comprehensive means of controlling the downstream inflammatory cascade and thus 446 
safely and effectively treating PsA’s diverse manifestations.  447 
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FIGURE LEGENDS 565 
Figure 1. Patient disposition through Week 24. Two patients (1-guselkumab q4w, 1-placebo 566 
were randomized in error and never treated). CRP – C-reactive protein, q4/8w – every 4/8 weeks, 567 
TB – tuberculosis, W/D – withdrawal 568 
Figure 2. Proportions of patients achieving ACR20 (A), ACR50 (B), ACR70 (C), and 569 
Psoriasis IGA (D) responses over time (FAS). ACR20/50/70 – American College of 570 
Rheumatology 20/50/70% improvement, FAS – full analyses set, IGA – Investigator’s Global 571 
Assessment, q4/8w – every 4/8 weeks  572 
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TABLES 573 
Table 1. Summary of baseline patient characteristics (FAS)  
 Guselkumab 100 mg  
Placebo 
q4w q8w 
Number of patients  245 248 246 
Age (years) 45·9 (11·5) 44·9 (11·9) 46·3 (11·7) 
Male, n (%) 142 (58%) 129 (52%) 117 (48%) 
White, n (%) 242 (99%) 240 (97%) 242 (98%) 
Body weight (kg) 85·8 (19·5) 83·0 (19·31) 84·0 (19·7) 
PsA duration (years) 5·53 (5·9) 5·11 (5·5) 5·75 (5·6) 
Number of swollen joints (0-66) 12·9 (7·8) 11·7 (6·8) 12·3 (6·9) 
Number of tender joints (0-68) 22·4 (13·5) 19·8 (11·9) 21·6 (13·06) 
Patient's assessment of pain (0-10 cm VAS) 6·2 (2·0) 6·3 (2·0) 6·3 (1·8) 
Patient's global assessment (arthritis, 0-10 cm VAS) 6·4 (1·9) 6·5 (1·9) 6·5 (1·8) 
Physician's global assessment (0-10 cm VAS) 6·6 (1·5) 6·6 (1·6) 6·6 (1·5) 
HAQ-DI score (0-3) 1·2 (0·6) 1.3 (0.6) 1·3 (0·6) 
CRP (mg/dL), median (IQR) 1·2 (0·6–2·3) 1·3 (0·7–2·5) 1·2 (0·5–2·6) 
Psoriatic BSA, % 18·2 (20%)  17·0 (21%) 17·1 (20%) 
IGA score=3/4, n (%) 117 (48%) 108 (44%) 115 (47%) 
PASI score (0-72) 10·8 (11·7) 9·7 (11·7) 9·3 (9·8) 
PsA-modified vdH-S score (0-528) 27·2 (42·2) 23·0 (37·8) 23·8 (37·8) 
Patients with enthesitis, n (%) 170 (69%) 158 (64%) 178 (72%) 
  Enthesitis (LEI) score (1-6)a 3·0 (1·7) 2·6 (1·5) 2·8 (1·6) 
Patients with dactylitis, n (%) 121 (49%) 111 (45%) 99 (40%) 
  Dactylitis score (1-60)b 8·6 (9·6) 8·0 (9·6) 8·4 (9·3) 
SF-36    
  PCS score 33·3 (7·1) 32·6 (7·9) 32·4 (7·0) 
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Table 1. Summary of baseline patient characteristics (FAS)  
 Guselkumab 100 mg  
Placebo 
q4w q8w 
  MCS score 48·4 (11·0) 47·4 (10·8) 47·2 (12·0) 
Patients with prior apremilast use, n (%) 5 (2%) 4 (2%) 4 (2%) 
Patients receiving at baseline, n (%)    
 DMARDs 170 (69%) 170 (68%) 172 (70%) 
   Methotrexate 146 (60%) 141 (60%) 156 (63%) 
  Dose (mg/week)  15·6 (5·0) 15·3 (5·2) 15·2 (4·6) 
 Oral corticosteroids for PsA 46 (19%) 50 (20%) 49 (20%) 
  Dose equivalent to prednisone (mg/day) 7·0 (2·4) 6·8 (2·5) 7·8 (2·5) 
 NSAIDs for PsA 171 (70%) 165 (66%) 168 (68%) 
Data presented are mean (SD) unless noted otherwise.  
a Among patients with LEI enthesitis score at baseline  (q4w, n=166; q8w, n=157; placebo, n=175)  
b Among patients with dactylitis score at baseline  (q4w, n=121; q8w, n=111; placebo, n=99)  
BSA – body surface area, CRP – C-reactive protein, DMARDs – disease-modifying antirheumatic drugs, FAS – full 
analysis set (randomised and treated patients), HAQ-DI – Health Assessment Questionnaire- Disability Index, IGA 
– Investigator’s Global Assessment, IQR -  interquartile range, LEI – Leeds Enthesitis Index, MCS – mental 
component summary, NSAIDs – nonsteroidal anti-inflammatory drugs, PASI – Psoriasis Area and Severity Index, 
PCS – physical component summary, PsA – psoriatic arthritis, q4w/q8w – every 4/8 weeks, SD – standard 
deviation, SF-36 – 36-item Short-Form, TNF – tumor necrosis factor, VAS – visual analog scale, vdH-S - van der 
Heijde-Sharp 
  574 
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 575 
Table 2. Summary of efficacy findings through Week24 (FASa) 
 Guselkumab 100 mg  
Placebo 
 q4w q8w 
Number of patients  245 248 246 
Primary endpoint    
ACR20 response at Week24, n (%) 156 (64%)   159 (64%)   81 (33%) 
  % difference vs placebo (95% CI) 31 (22, 39)  31 (23, 40)  
  US procedureb-adjusted p value <0·0001 <0·0001  
Major secondary endpoints controlled by US procedure   
Psoriasis IGA response at Week24c, n/N (%) 126/184 (68%)  124/176 (70%)  35/183 (19%) 
  % difference vs placebo (95% CI) 50 (41, 58) 51 (42, 60)  
  US procedureb-adjusted p value <0·0001 <0·0001  
HAQ-DI, LSmean (95% CI) change at Week24  -0·40 (-0·46, -0·34) -0·37 (-0·43, -0·31) -0·13 (-0·19, -0·07) 
  LSmean difference vs placebo (95% CI) -0·27 (-0·35, -0·19) -0·24 (-0·32, -0·15)  
  US procedureb-adjusted p value <0·0001 <0·0001  
PsA-modified vdH-S,  Median (IQR) change at 
Week24 
0·00 (-0·50–0·50)  0.00 (-0.50–1.00) 0·00 (0·00–1·00) 
 LSmean (95% CI) change at Week24 0·29 (-0·05, 0·63) 0·52 (0·18, 0·86) 0·95 (0·61, 1·29) 
  LSmean difference vs placebo (95% CI) -0.66 (-1.13, -0.19) -0·43 (-0·90, 0·03)  
  US procedureb-adjusted p value 0·0110 0·07  
SF-36 PCS, LSmean (95% CI) change at Week24  7·04 (6·14, 7·94) 7·39 (6·50, 8·29) 3·42 (2·53, 4·32) 
  LSmean difference vs placebo (95% CI)  3·62 (2·39, 4·85) 3·97 (2·75, 5·20)  
  US procedureb-adjusted p value 0·0110 0·0110  
SF-36 MCS, LSmean (95% CI) change at Week24 4·22 (3·14, 5·29) 4·17 (3·10, 5·23) 2·14 (1·07, 3·22) 
  LSmean difference vs placebo (95% CI) 2·07 (0·60, 3·54)  2·02 (0·56, 3·49)  
  US procedureb-adjusted p value 0·07 0·07  
Major secondary endpoints not controlled by US procedure   
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ACR20 response at Week16, n (%) 137 (56%) 137 (55%)  83 (34%)  
  % difference vs placebo (95% CI) 22 (14, 31) 22 (13, 30)   
  Unadjusted p valued <0·0001 <0·0001  
ACR50 response at Week24, n (%) 81 (33%) 78 (32%)  35 (14%)  
  % difference vs placebo (95% CI) 19 (12, 26) 17 (10, 24)   
  Unadjusted p valued <0·0001 <0·0001  
ACR50 response at Week16, n (%) 51 (21%)  71 (29%)  23 (9%) 
  % difference vs placebo (95% CI) 12 (5, 18) 19 (13, 26)  
  Unadjusted p valued 0·0004 <0·0001  
ACR70 response at Week24, n (%) 32 (13%) 46 (18%)  10 (4%)  
  % difference vs placebo (95% CI)   9 (4, 14) 14 (9, 20)  
  Unadjusted p valued 0·0004 <0·0001  
DAS28-CRP, LSmean (95% CI) change at Week24  -1·62 (-1·76, -1·49) -1·59 (-1·72, -1·45) -0·97 (-1·11, -0·84) 
  LSmean difference vs placebo (95% CI) -0·65 (-0·83, -0·47) -0·61 (-0·80, -0·43)  
  Unadjusted p valued <0·0001 <0·0001  
Additional secondary endpoints not controlled by US procedure   
HAQ-DI improvement ≥0.35e at Week24, n/N (%) 128/228 (56%)  114/228 (50%)  74/236 (31%) 
  % difference vs placebo (95% CI) 24 (16, 33) 19 (10, 27)  
  Unadjusted p valued <0·0001 <0·0001  
PASI75 response at Week24c, n/N (%)  144/184 (78%)  139/176 (79%)  42/183 (23%) 
  % difference vs placebo (95% CI) 55 (47, 64) 56 (47, 64)  
  Unadjusted p valued <0·0001 <0·0001  
PASI90 response at Week24 c, n/N (%) 112/184 (61%) 121/176 (69%) 18/183 (10%) 
  % difference vs placebo (95% CI) 51 (43, 59) 59 (51, 67)  
  Unadjusted p valued <0·0001 <0·0001  
PASI100 response at Week24c, n/N (%) 82/184 (45%) 80/176 (46%) 5/183 (3%) 
  % difference vs placebo (95% CI) 42 (35, 50) 42 (35, 50)  
  Unadjusted p valued <0·0001 <0·0001  
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MDA response at Week24, n (%) 46 (19%) 62 (25%) 15 (6%) 
  % difference vs placebo (95% CI) 13 (7, 18) 19 (13, 25)  
  Unadjusted p valued <0·0001 <0·0001  
Patients meeting treatment-failure criteria (13 [5%] q4w, 12 [5%] q8w, and 17 [7%] placebo patients) were considered 
nonresponders for binary clinical endpoints and as having  no improvement from baseline for continuous clinical endpoints. After 
application of treatment failure rules, there were limited instances of patients with missing data (ACR20: 2 q8w, 1 placebo; 
DAS28-CRP: 2 q8w, 3 placebo;  IGA: 1 per group;  HAQ-DI: 2 q8w, 2 placebo; vdH-S: 5 q4w, 1 q8w, 1 placebo; PCS/MCS: 2 
q8w, 2 placebo; PASI: 1 per group; enthesitis/dactylitis resolution: 1 q8w, 1 placebo). Missing data were imputed as 
nonresponders for binary clinical endpoints; multiple imputation was used to impute missing data for continuous clinical 
endpoints assuming missing at random and using the predicted value from the Full Conditional Specification regression method 
(requiring 200 successful imputations) for any missing pattern. Each variable eligible for imputation was to be restricted to only 
impute within its possible range of values. Treatment differences for binary endpoints were assessed via Cochran-Mantel-
Haenszel test, and those for continuous endpoints were assessed via an analysis of covariance model. All models included 
treatment group, baseline non-biologic DMARD use (yes/no), most current CRP value prior to randomization 
(<2·0/≥2·0 mg/dL), and baseline value as explanatory factors. Continuous radiographic endpoints were compared using an 
analysis of covariance test; missing data were assumed to be missing at random and were imputed using multiple imputation. The 
95% CIs surrounding the % differences vs. placebo were determined based on the Wald statistic.  
a The FAS included all randomised and treated patients. 
b See Figure S1A. 
c Assessed in patients with ≥3% BSA affected by psoriasis and IGA score ≥2 at Week0. 
d Unadjusted (nominal) p values are not controlled for multiplicity and should be interpreted only as supportive. 
e Assessed in patients with HAQ-DI ≥0·35 at Week0. 
ACR20/50/70 – American College of Rheumatology 20/50/70% improvement, CI – confidence interval, DAS28-CRP – 28-joint 
Disease Activity Score based on C-reactive protein, FAS – full analysis set, HAQ-DI – Health Assessment Questionnaire-
Disability Index, IGA – Investigator’s Global Assessment, LS – least squares MCS – mental component summary, MDA – 
minimal disease activity, PASI/75/90/100 – Psoriasis Area and Severity Index 50/75/90/100% improvement, PCS – physical 
component summary,  q4/8w – every 4/8 weeks, SF-36 – 36-item Short Form, PsA – psoriatic arthritis, US – United States, vdH-S 
– van der Heijde-Sharp 
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Table 3. Summary of Dactylitis and Enthesitis Results at Week 24 (FASa)  
 Guselkumab 100 mg  
Placebo 
 q4w q8w 
Major secondary endpoints controlled by US procedureb 
DISCOVER-1 + DISCOVER-2 Pooled 
Resolution of dactylitis, n/N (%)  101/159 (64%)  95/160 (59%)  65/154 (42%) 
 % difference vs placebo (95% CI) 21 (10, 32) 18 (7, 29)  
   US procedure-adjusted p value 0·0110 0·0301   
Resolution of enthesitis, n/N (%) 109/243 (45%)  114/230 (50%)  75/255 (29%) 
 % difference vs placebo (95% CI) 15 (6, 23) 20 (12, 28)  
   US procedure-adjusted p value 0·0301  0·0301   
Major secondary endpoints not controlled by US procedurec   
DISCOVER-1 + DISCOVER-2 Pooled 
Dactylitis score, LSmean (95% CI) change  -5·97 (-6·84, -5·11) -6·10 (-6·92, -5·27) -4·21 (-5·05, -3·36) 
  LSmean difference vs placebo (95% CI) -1·77 (-2·87, -0·66) -1·89 (-2·99, -0·79)  
  Unadjusted p value 0·0025 0·0020  
Enthesitis LEI score, LSmean (95% CI) change  -1·59 (-1·79, -1·38) -1·52 (-1·73, -1·31) -1·02 (-1·22, -0·82) 
  LSmean difference vs placebo (95% CI) -0·57 (-0·83, -0·31) -0·50 (-0·77, -0·23)  
 Unadjusted p value 0·0017 0·0003  
See Table 2 for further details of statistical testing. 
a The FAS included all randomised and treated patients. 
b Per the preplanned statistical analysis plan, resolution of dactylitis and enthesitis data were combined across DISCOVER-1 and 
DISCOVER-2 as major secondary endpoints in the US testing procedure (See Figure S1A). 
c Unadjusted (nominal) p values are not controlled for multiplicity and should be interpreted only as supportive. 
CI – confidence interval, FAS – full analysis set, LEI – Leeds Enthesitis Index, LS – least squares, q4/8w – every 4/8 weeks, US – 
United States 
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Table 4. Summary of safety results through Week 24 (SAS) 
 Guselkumab 100 mg  
Placebo 
 q4w q8w Combined 
Number of patients  245 248 493 246 
Mean length of follow up (weeks) 23·8 23·9 23.9 24·0 
Mean number of administrations 5·9 5·9 5.9 5·9 
Patients with 1 or more AE, n (%)  113 (46%) 114 (46%) 227 (46%) 100 (41%) 
  AEs occurring in ≥3% of patients in any group (in alphabetical order) 
Alanine aminotransferase increased  25 (10%) 15 (6%) 40 (8%) 11 (4%) 
Aspartate aminotransferase increased 11 (4%) 14 (6%) 25 (5%) 6 (2%) 
  Bronchitis 10 (4%) 1 (<1%) 11 (2%) 3 (1%) 
Nasopharyngitis 12 (5%) 10 (4%) 22 (4%) 9 (4%) 
Upper respiratory tract infection 12 (5%) 6 (2%) 18 (4%) 8 (3%) 
Patients with 1 or more SAE, n (%) 8 (3%)a 3 (1%)b  11 (2%) 7 (3%)c 
Patients with AE resulting in study drug d/c, n (%) 6 (2%)d 2 (1%)e  8 (2%) 4 (2%)f 
MACE, n (%) 1 (<1%) 0 1 (<1%) 0 
Malignancy, n (%) 0 1 (<1%) 1 (<1%) 1 (<1%) 
Patients with infectionsg, n (%) 49 (20%) 40 (16%)  89 (18%) 45 (18%)  
  Serious infections 3 (1%)  1 (<1%)  4 (1%) 1 (<1%)  
Patients with injection-site reactions, n (%) 3 (1%)  3 (1%)  6 (1%) 1 (<1%)  
Patients with suicidal ideation, n (%) 1 (<1%)  0  1 (<1%) 1 (<1%)  
a 1 patient each with acute hepatitis B, blue toe syndrome, femur fracture, influenza pneumonia, ischaemic stroke, lower limb 
fracture/metal poisoning, oophoritis, osteoarthritis. 
b 1 patient each with ankle fracture, coronary artery disease, pyrexia. 
c 1 patient each with clear cell renal cell carcinoma, isoniazid-induced liver injury, inflammatory bowel disease (suspected), 
obesity, post-procedural fistula, tubulointerstitial nephritis, unstable angina. 
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Table 4. Summary of safety results through Week 24 (SAS) 
 Guselkumab 100 mg  
Placebo 
 q4w q8w Combined 
d 1 patient each with acute hepatitis B (de novo), allergic dermatitis, isoniazid-induced liver injury, ischaemic stroke, rhinovirus 
infection, and injection-site erythema/swelling/warmth. 
e 1 patient each with rash, malignant melanoma in situ. 
f 1 patient each with clear cell renal cell carcinoma, isoniazid-induced liver injury, inflammatory bowel disease, 
tubulointerstitial nephritis 
g AEs identified by investigators as infections 
AE – adverse event, d/c – discontinuation, MACE – major adverse cardiovascular event, q4/8w – every 4/8 weeks, SAE – 
serious adverse event, SAS – safety analysis set (treated patients) 
577 
 
 
41 
 
Figure 1.  
 
 
  
 
 
42 
 
Figure 2. 
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